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9ABSTRACT
Firstly, the pattern of prescription drug use has not been investigated extensively in the Finnish
pregnant population. Secondly, it is not known to what extent drugs which may cause fetal adverse
effects are used during pregnancy. Thirdly, with the increasing use of antidepressants, possible
harmful effects of the selective serotonin reuptake ihibitors (SSRIs) on pregnancy outcome warrant
investigation to avoid serious public health consequences. Fourthly, valproic acid is a major
anti-epileptic drug with an established teratogenic potential. Hereditary susceptibility to valproate
teratogenicity may explain why some infants are affected, while the majority are born healthy after
exposure to valproate in utero.
The overall use of prescription drugs, and the use of prescription drugs suspected or known to be
harmful to the fetus were investigated in pregnant women during different pregnancy trimesters, and
in matched non-pregnant controls (n=43 470 each). Safety of SSRIs was evaluated by comparing
women with SSRI purchases with matched pregnant controls without drug purchases (n=1782 each),
and also by comparing women with SSRI purchases in different trimesters. Data for these three
studies were derived from nationwide registers. The aetiology of multiple malformations was
investigated by clinical evaluation and review of medical records of three sets of siblings, all
exposed to valproate in utero, and their parents.
Prescription drugs were purchased by 46.2% of pregnant women, compared with 55.2% of
non-pregnant controls. Drug treatment for chronic illnesses requiring treatment continued
throughout pregnancy. In the second study, potentially or clearly harmful drugs were used less
frequently in the first trimester than in the preconception period. In the third study, first trimester
exposure to SSRIs (n = 1398) was not associated with an increased risk of major malformations
(adjusted OR 1.0, 95% CI 0.6-1.7). Admission to special or intensive care unit was more common in
neonates exposed to SSRIs during the third trimester than in those exposed only during the first
trimester (15.7% vs. 11.2%; adjusted OR 1.6, 95% CI 1.1-2.2). In the fourth study, all three sets of
siblings exposed to valproate in utero had developmental delay and a distinctive facial appearance,
including a broad nasal root, anteverted nares, and a shallow philtrum, and other malformations
characteristic of valproate embryopathy.
The results of prescription drug use are in line with rational drug use during pregnancy. Due to the
relatively common occurrence of neonatal problems, SSRI drugs should be used during pregnancy
only when clearly indicated. The observed valproate embryopathy in all siblings in the three
families strongly suggests hereditary susceptibility to valproate-induced teratogenicity, as, in
general, the majority of children are born healthy.
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1. INTRODUCTION
Major congenital malformations occur in approximately 2% to 3% of all pregnancies, placing a
considerable burden on the affected child, the family and society. In more than half of the cases, the
aetiology of the malformation remains unknown (Kalter 2003). For many drugs, including ones
recently marketed, data are inadequate to confirm their safe use during pregnancy (Lo and Friedman
2002). Consequently, prescribing drugs during pregnancy presents a challenge in balancing optimal
treatment of maternal disease against possible harm to the fetus. On the other hand, when adequate
information on drug safety is lacking, essential drug treatment may be avoided, and chronic illnesses
requiring drug treatment may be treated suboptimally.
Extensive studies investigating overall use of prescription drugs during pregnancy have not
previously been conducted in Finland. One Finnish study, based on prospectively collected
interview data for nearly 8000 pregnant women, reported that 1.5% of subjects used psychotropic
drugs during pregnancy (Larivaara et al.1996). However, no data concerning other drug groups were
available (Larivaara et al. 1996). Several reports from other countries have suggested extensive use
of prescription and over-the-counter (OTC) drugs during pregnancy, indicating marked cultural
variation in drug use patterns (Collaborative Group on Drug Use in Pregnancy (CGDUP) 1992;
Rubin et al. 1993; Olesen et al. 1999a; de Vigan et al. 1999; Lacroix et al. 2000).
Large cultural variations in drug use during pregnancy have also been observed in studies
classifying drugs according to fetal safety (CGDUP 1991; Olesen et al. 1999b; Lacroix et al. 2000).
Pregnancies are often unplanned and harmful exposure may occur by accident. First-trimester
exposure to a harmful agent may cause structural malformations, but if first-trimester exposure is
avoided many drugs may be used relatively safely during the second or third trimester. However,
some drugs are known to affect the fetus during the later stages of pregnancy (Barr 1994; Kalter
2003). Surveillance of drug use during pregnancy, and identification of drug prescription practices
are therefore important.
The prevalence of major depression in pregnancy is 5-10%, and up to 20% of pregnant women
experience some depressive symptoms (Gotlib et al. 1989; Pajulo et al. 2001; Burt and Stein 2002;
Gavin et al. 2005). In the last decade, consumption of the newer antidepressants, including selective
serotonin reuptake inhibitors (SSRIs), has been steadily increasing in the population (Finnish
Statistics on Medicines 2003). No increased risk of major malformations has been confirmed, but
most studies have been based on small numbers of exposed. Several case reports and studies have
suggested an increased risk of neonatal complications, related to drug withdrawal or serotonergic
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overstimulation, after exposure to SSRIs in the third trimester (Chambers et al. 1996; Isbister et al.
2001; Costei et al. 2002). Severe symptoms in the neonate may also contribute to adverse
neurodevelopment (Hernandez-Diaz and de Abajo 2003).
The anti-epileptic drug valproic acid is an established teratogen (Yerby 1994, 2000; Polifka and
Friedman 2002). However, adequate treatment of epilepsy and seizure control are important also
during pregnancy, and the mother should be treated optimally. At present, valproate is also being
used in other medical conditions, including bipolar disorders and migraine prophylaxis (Freitag et
al. 2002; Viguera et al. 2002). Existence of a valproate-specific embryopathy with characteristic
malformations has been proposed (Clayton-Smith and Donnai 1995). In addition to malformations,
several case reports and studies suggest an increased risk of drug-related adverse effects on
neurodevelopment (Koch et al. 1996; Adab et al. 2001; Kozma 2001). One recent, carefully
conducted prospective Finnish study has suggested detrimental effects of intrauterine valproate
exposure on the intellectual development of preschool and school-age children (Gaily et al. 2004).
Hereditary factors may predispose to valproate teratogenicity, as in general, the majority of children
are born healthy.
2. REVIEW OF THE LITERATURE
2.1. Drugs as teratogens
2.1.1. History
 The role of exogenous agents − other than ionizing radiation − in producing abnormal fetal
development in humans was not recognized until 1941, when the association between maternal
rubella virus infection and embryo-fetal maldevelopment was established (Gregg 1941). Soon
thereafter, experimental studies showed that vitamin deficiency could alter normal morphogenesis
(Warkany and Schraffenberger 1943). Furthermore, exposure to certain chemicals and drugs was
shown to interfere with normal development in experimental animal studies as well as in human
trials (Gillman et al. 1948; Thiersch 1952). One decade later, the thalidomide tragedy resulted in the
births of 6000 – 8000 malformed babies worldwide, however, this number does not include the
probably considerable number of abortions and fetal deaths associated with thalidomide exposure
(Lenz 1988; Schardein 2000; Kalter 2003). The first report of a suspected association between
thalidomide and severe congenital malformations was published in 1961 by McBride (McBride
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1961). Typical malformations were bilateral shortened or missing limbs (phocomelia or amelia), but
defects in other organ systems (gastrointestinal, cardiovascular, eye and ear anomalies) were also
common (Mellin and Katzenstein 1962; Smithells 1973; Lenz 1988; Shepard 1992; Smithells and
Newman 1992). The drug had been tested for teratogenicity in rodents without an apparent risk of
producing birth defects and was considered and marketed as safe (Mellin and Katzenstein 1962;
Lenz 1990). As a practical consequence, amendments were introduced to tighten control over drugs
at the investigational level, and requirements for drug safety testing in animals and humans
increased (Anonymous 1962; Tuchmann-Duplessis 1972; Schardein 1988; Schardein 2000; Food
and Drug Administration FDA 2005). Furthermore, research in the fields of basic, clinical and
epidemiologic environmental teratogenesis increased, and malformation registers and teratology
information services were established in many parts of the world to prevent the occurrence of a
similar disaster (Clementi et al. 2002; Reefhuis et al. 2002).
In addition to structural malformations, drugs and chemicals were also observed to be able to induce
other adverse effects. Impaired growth and neurodevelopment were associated with ethanol
exposure (Jones and Smith 1973; Jones et al. 1973). Transplacental carcinogenesis was established
upon discovery of an association between a cluster of young women with vaginal adenocarcinoma
and exposure to diethylstilbestrol (DES) in utero (Herbst and Scully 1970; Herbst et al. 1971).
2.1.2. Role of placenta
The fertilized ovum attaches to the uterine endometrium six days after fertilization, and by the end
of the third week of development anatomical circumstances necessary for physiological exchanges
between the mother and the embryo are established (Scialli 1992; Moore and Persaud 2003). In the
human placenta, the circulations of the mother and the fetus are separated by the placental
membrane, consisting of a single layer of cytotrophoblasts − partially disappearing as pregnancy
proceeds −, syncytiotrophoblasts with the underlying basement membrane, and the fetal capillary
endothelial cells (van der Aa et al. 1998; Audus 1999; Ganapathy et al. 2000). A major function of
the placenta is to enable the transfer of oxygen and nutrients from the mother to the fetus, and to
eliminate metabolic waste products from the fetus (Enders and Blankenship 1999; Ganapathy et al.
2000).
Most endogenous and exogenous substances are transferred across the placenta (Pacifici and Nottoli
1995; Hakkola et al. 1998; Audus 1999). Drugs cross the placenta mainly by passive diffusion
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(Syme et al. 2004; Myllynen et al. 2005). Lipophilic, unionized and unbound drugs with a low
molecular weight (<500-600 D) cross biological membranes more easily than lipophobic, polar
compounds bound to plasma proteins (Pacifici and Nottoli 1995). Drugs with a molecular weight
>1000 D cross the membrane very poorly. Since most drugs have a molecular weight <500 D, size
rarely limits the rate of drug transfer through the placenta (Pacifici and Nottoli 1995). The placenta
also expresses several transporter proteins, which are relevant in nutrient transfer to the fetus and
may also actively contribute to the functional barrier between maternal and fetal circulations (Knipp
et al. 1999; Ganapathy et al. 2000). While transporters, such as P-glycoprotein (P-gp), may protect
the embryo or the fetus from toxic exposures by actively preventing xenobiotics from entering the
fetal compartment, inhibition of function of these proteins may increase fetal susceptibility to drug-
induced teratogenicity, and some of them may actually facilitate drug transportation from the mother
to the fetus (Audus 1999; Ganapathy et al. 2000; Young et al. 2003; Ganapathy and Prasad 2005;
Mölsä et al. 2005). The polymorphism observed in the multidrug resistance 1 (MDR1) gene
encoding P-gp and resulting in inter-individual variability in P-gp tissue expression may play a role
in determining individual drug response (Fromm 2004). The clinical implications in the human
placenta are, however, currently unknown (Young et al. 2003).
The human fetus and placenta are capable of metabolizing drugs (Hakkola et al. 1996, 1998).
Enzymatic drug-metabolizing activity has been documented in the fetal liver as early as the seventh
or eighth week of pregnancy (Pelkonen 1973; Blake et al. 2005). However, due to the small size of
the fetus and low placental enzyme activity, the contribution of feto-placental metabolism to the
overall drug elimination capacity is probably minor (Hakkola et al. 1998; Loebstein and Koren
2002).
2.1.3. Factors determining teratogenicity
2.1.3.1. Dose and timing of exposure
Teratogenic induction is a dose- and time-dependent phenomenon. The dose-response determines
whether a true teratogenic effect exists (Brent 2004a). In addition to the nature of the exposure and
the dose, the timing of exposure is critical (Kalter 2003, Brent 2004a). The exposure must occur at a
sensitive stage of development to cause malformations (Brent et al. 1993). Toxic exposures during
the first two weeks after fertilization, i.e. during the pre-differentiation period, are considered
unlikely to cause congenital malformations in human embryos, as the cells of the conceptus are
pluripotent at this stage, and consequently, cells that are killed can be replaced by other cells
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(Polifka and Friedman 2002). However, embryonic death and abortion may occur (Brent and
Beckman 1994). During the organogenetic period (weeks 3-8 postconception) the embryo is most
sensitive to teratogenic exposures and structural malformations are produced (Polifka and Friedman
2002, Brent 2004a). The harmful exposure must have taken place prior to differentiation of the
particular malformed organ if causality between an exposure and structural malformation is
suspected.
2.1.3.2. Genetic susceptibility
All species are not equally susceptible to the developmental toxic influence of a given chemical. An
agent that is teratogenic in one species may have little or no teratogenic effect in another species, or
may produce entirely different defects (Warkany 1947; Jelovsec et al. 1989; Brent et al. 1993; Brent
2004b). The mechanisms involved in embryonic development differ between species, therefore
determining drug-specific susceptibility (Schardein 2000). Similarly, there are genetic differences
within species that may influence the teratogenic response (Shepard 1982). Polymorphisms in
maternal or fetal genes can modify the individual susceptibility to adverse effects of exogenous
agents (Cummings and Cavlock 2004). In humans, genetic predisposition for teratogenicity in the
mother has been postulated for several agents (Strickler et al. 1985; Dean et al. 1999). In addition,
polymorphism in fetal drug metabolizing enzyme expression or polymorphism in placental transport
protein expression may contribute to individual pharmacological and teratogenic responses in the
fetus (Lankas et al. 1998; Chen et al. 2000; Hakkola et al. 2001).
2.1.4. Manifestations of developmental toxicity
A teratogen is defined as any exogenous agent capable of causing abnormal fetal development,
mainly structural malformations (Schardein 2000). However, there are several recognized
manifestations of developmental toxicity. In addition to malformations deviant development may
manifest as growth retardation, embryo-fetal death, functional impairment or transplacental
carcinogenesis (Shepard and Fantel 1979; Kalter and Warkany 1983b; Abel 1984; Brent and
Beckman 1994; Mittendorf 1995; Mantovani and Calamandrei 2001). The known human teratogenic
drugs are presented in Table 1.
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2.1.4.1. Definition and prevalence of congenital malformations
Major congenital malformations are defined as physical defects causing a significant functional
disturbance and requiring medical or surgical intervention (Kalter 2003). They occur at a frequency
of 20-40:1000 live-births (Schardein 2000; Kalter 2003). Minor congenital anomalies are relatively
mild physical divergences from the normal, with little or no medical or cosmetic consequence
(Kalter 2003). The prevalence of minor congenital anomalies has been reported to vary between 14-
45%, depending on what is considered a normal phenotypic variant (Marden et al. 1964; Holmes et
al. 1985; Kalter 2003). The presence of several minor malformations is predictive of a major
malformation (Leppig et al. 1987). The aetiology of most malformations is unknown. However,
drug-induced birth defects are estimated to account only for 1% of all birth defects (Kalter and
Warkany 1983a; Kalter 2003; Brent 2004a).
2.1.4.2. Relevance of animal studies to humans
Animal teratology studies are helpful in raising concerns about the reproductive effects of drugs and
chemicals. However, negative results in animal studies do not guarantee that these agents are safe in
humans (Brown and Fabro 1983; Jelovsek et al. 1989). All agents that have produced human
developmental toxicity have also been developmental toxicants in some animal species at doses that
are not toxic to the mother (Brown and Fabro 1983; Koren et al. 1998). Nevertheless, all animal
species are not similarly susceptible to human teratogens (Jelovsek et al. 1989; Scialli 1992). As an
example, thalidomide was not teratogenic in standard teratology testing in rodents but induced
malformations in rabbits and non-human primates (Scialli 1992). In an analysis comparing positive
and negative teratogenicity testing in animals for their ability to identify human teratogens, animal
developmental toxicity tests had a positive predictive value of 75-100% and a negative predictive
value of 64-91% (Jelovsek et al. 1989; Scialli 1992). Thus, while animal studies can provide
valuable information pertaining to vulnerability of chemicals and drugs, they should be interpreted
with caution when applied to risk assessment in humans (Brent 2004b).
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2.1.5. Drug safety classifications during pregnancy
Drug safety classifications group drugs according to fetal safety. The classification is based on
human experience, and when unavailable, on animal data. The purpose of these classifications is to
give information to health care professionals about possible or established risk or safety of using
drugs during pregnancy (Alvan et al. 1995; Doering et al. 2002). These classifications can also be
used in epidemiological research to study drug choice during pregnancy. Significant differences
exist between the established classification systems in the distribution of drugs into risk categories
(Addis et al. 2000). The Swedish classification (Swedish System of Approved Drugs (FASS) 1993)
differs considerably from the Food and Drug Administration (FDA) classification (Briggs et al.
2002), the latter having been criticized for being of questionable value in clinical settings (Friedman
1993; Sannerstedt et al. 1996; Uhl et al. 2002). The classification system adopted by the Australian
Drug Evaluation Committee (ADEC 1996) is only slightly modified from the Swedish system
(Addis et al. 2000) (Table 2). The recently established EU classification divides drugs into ten
different categories, and also includes interactions with oral contraceptives and possible male-
mediated effects (European Medicines Agency EMEA 2005). This classification is currently under
review.
2. 2. Use of drugs during pregnancy
2. 2. 1. General aspects
For the vast majority of drugs, insufficient data exists for reliable assessment of fetal risk (Lo and
Friedman 2002). While unnecessary and harmful drug treatments should be avoided during
pregnancy, diseases requiring drug treatment must be treated adequately (Czeizel 2001). If left
untreated, exacerbation of the mother’s illness not only jeopardizes the mother’s health but also the
well-being of the fetus. According to several studies, drug use during pregnancy is extensive (Olesen
et al. 1999a; de Vigan et al. 1999; Donati et al. 2000; Lacroix et al. 2000). However, differences in
the study methods used to ascertain drug exposure, and heterogeneous categorization of drugs make
comparisons of results difficult (Bonassi et al. 1994; Nordeng et al. 2001a). Socio-demographic
factors associated with drug use include maternal illness, smoking, country of residence, education
and parity (Buitendijk and Bracken 1991; Rubin et al. 1993; Bonassi et al. 1994; de Vigan et al.
1999), maternal illness obviously being the most important factor in determining drug use (Donati et
al. 2000; Nordeng et al. 2001a).
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2. 2. 2. Studies based on interviews
In studies based on interviews, use of OTC drugs and vitamins can be included in the assessment. A
collaborative study, under the auspices of the World Health Organization (WHO), assessed drug use
during pregnancy in several European countries, also including countries outside Europe
(Collaborative Group of Drug Use in Pregnancy (CGDUP) 1991, 1992) (Table 3a). Of the nearly
15 000 women interviewed, 86% had taken at least one drug during pregnancy. The use of most
drugs had increased from the first to the third trimester, and the use of drugs classified as potentially
harmful or harmful (ADEC categorizations B3, C, D, X), had increased throughout pregnancy
(CGDUP 1991) (Table 3b). The study also revealed a number of differences in drug-utilization
profiles between countries, reflecting cultural differences in medical care and public health policies
(CGDUP 1992).
Large differences between European countries were also found in a multicentre study focusing on
first-trimester drug use, in which more than 1000 mothers of healthy newborns were interviewed
after delivery (de Vigan et al. 1999). In this study, 36% of all women reported drug use during the
first trimester, the rate varying from 23% to 50% according to the centre (de Vigan et al. 1999)
(Table 3a). Two Italian studies showed relatively similar drug exposure profiles (Bonassi et al. 1994;
Donati et al. 2000), differing from results derived from other European studies (Irl and Hasford
1997; Olesen et al. 1999a; de Vigan et al. 1999; Nordeng et al. 2001a) (Table 3a). A recently
published study from Norway reported increasing use of most drug groups with progression of
pregnancy (Nordeng et al. 2001a). The authors did, however, point out that the study material was
collected during 1986-1988 and may not reflect today’s practice of drug use in pregnancy (Nordeng
et al. 2001a).
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Table 2. Pregnancy safety classifications. FASS = Swedish classification, ADEC = Australian
classification, FDA = American classification.
Classification Pregnancy category definition
FASS
A Drugs taken by a large number of pregnant women with no proven increase in the
frequency of malformations or other observed harmful effects on the fetus
B1 Limited experience in pregnant women, no increase observed in the frequency of
malformations or other observed harmful effects on the fetus
Animal studies reassuring
B2 Limited experience in pregnant women, no increase observed in the frequency of
malformations or other harmful effects on the fetus
Animal studies inadequate or lacking
B3 Limited experience in pregnant women, no increase observed in the frequency of
malformations or other harmful effects on the fetus
Animal studies have shown evidence of an increased occurrence of fetal damage
C May cause pharmacological adverse effects on the fetus or neonate
D Suspected or proven to cause malformations or other irreversible damage on the fetus
ADEC
A-D Categories A; B1, B2, B3, C, D similar to the FASS definitions
X High risk of causing permanent damage to the fetus. Contraindicated in pregnancy
FDA
A Controlled studies fail to demonstrate a risk to the fetus in the first trimester. Fetal harm
appears remote
B No controlled studies in humans, animal studies indicate no risk. Well-controlled studies in
humans show no risk, and animal studies show an adverse effect on the fetus
C No controlled studies in women. Animal studies indicate risk or are lacking
D Existing evidence of fetal risk in humans, benefits may outweigh risks in certain situations
X Risk clearly outweighs any possible benefit. Contraindicated in pregnancy
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2. 2. 3. Studies based on prescription and pharmacy registers
Register-based studies are cost-effective and allow large population-based samples to be analysed.
In addition, recall bias present in studies based on interviews can be avoided. However, complete
data on drug intake are lacking. Register-based studies include only prescription drugs, and
therefore, the use of OTC drugs and herbal medicines can not be assessed.
No previous register-based studies investigating overall prescription drug use during pregnancy in
the Finnish population have been published. In a large Danish study based on pharmacy records and
including 16 000 pregnant women, 44% of the women received prescriptions for one or more drugs
during pregnancy (Olesen et al. 1999a) (Table 3a). The majority of prescriptions (29%) were for
antibiotics. Anti-epileptic drugs were prescribed in a constant manner throughout pregnancy, but no
data were given regarding possible changes in utilization of drugs for other chronic illnesses such as
asthma or diabetes (Olesen et al. 1999a).
2. 2. 4. Pharmacoepidemiological studies on drug use assessing fetal risk according to drug
safety classifications
A study based on the material of their previous report (Olesen et al. 1999a) assessed potential risks
related to drug use in pregnancy using the FASS classification (Olesen et al. 1999b). Prescriptions
for drugs considered safe (category A) had increased, while prescriptions for potentially harmful
drugs (categories B3, C and D in the study, see Table 2), filled by nearly 20% of pregnant women,
were prescribed less often during the course of pregnancy (Olesen et al. 1999b) (Table 3b).
A recently published study from France showed that 99% of women received one or more
prescription drugs during pregnancy, the average number of different drug preparations being 13.6
per woman (Lacroix et al. 2000). In this study, 59% of pregnant women had received one or more
prescriptions for drugs belonging to FDA category D (positive evidence of human fetal risk but
benefits in pregnant women deemed acceptable), and 1.6% had received prescriptions for drugs
contraindicated in pregnancy (Lacroix et al. 2000) (Tables 3a and 3b). Furthermore, 78.9% of
pregnant women had received prescriptions of drugs for which there were no data available for
safety in pregnancy (Lacroix et al. 2000). The authors concluded that too many pregnant women are
exposed to drugs with established or unknown risk, and emphasized the need for continuous
monitoring of drug use during pregnancy.
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2. 3. Safety of the selective serotonin reuptake inhibitors during pregnancy
2. 3. 1. General aspects
The prevalence of major depression during pregnancy is approximately 10%, and up to 20% of
pregnant women have definable depressive symptoms (O’Hara 1986; Gotlib et al. 1989; Pajulo et al.
2001; Burt and Stein 2002). Non-medical treatment is effective especially in mild and moderate
major depression, but antidepressants are also often needed. The selective serotonin reuptake
inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline and fluvoxamine) are used primarily
to treat depression and anxiety disorders (Masand and Gupta 1999). They have a favourable side-
effect profile, and accordingly, are being used increasingly (Goldstein and Goodnick 1998).
However, no epidemiologic studies evaluating the use of SSRIs in the pregnant population have
been conducted. Several studies assessing the safety of SSRIs in pregnancy have been based on
relatively small subject pools (Pastuszak et al. 1993; Chambers et al. 1996; Kulin et al. 1998;
Chambers et al. 1999). Furthermore, study designs and methods for detecting adverse pregnancy
outcome have varied, making it difficult to draw conclusions. If the safe use of an antidepressant
during pregnancy has not been established, physicians may hesitate in prescribing it to pregnant
women even when clearly indicated. Moreover, inadequate treatment of maternal major depression
may lead to worsening of the condition, and discontinuation of maintenance antidepressant
treatment is associated with high rates of relapse (Nonacs and Cohen 2002).
2. 3. 2. Risk of major malformations
No definitive evidence of an increased risk of malformations associated with the use of SSRI drugs
has been reported to date. While most data concern fluoxetine and citalopram, less is known about
paroxetine, sertraline and fluvoxamine. The rate of major malformations was no higher in infants
exposed to fluoxetine in the first trimester than in the non-exposed control group in two studies
based on prospectively collected exposure data (Pastuszak et al. 1993; Chambers et al. 1996). In one
of these studies, the presence of three or more minor malformations was more common in the
exposed infants than in non-exposed controls (Chambers et al. 1996). However, no pattern of
malformations was recognized. The authors stated that, in general, infants with three or more minor
malformations are at increased risk of having an associated major malformation (Chambers et al.
1996). As some major malformations may stay occult, such as defects in brain development, this
finding could raise concerns of an associated developmental defect in the central nervous system,
detected only later in life (Chambers et al. 1996). No increased risk of major malformations was
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found in the fluoxetine pregnancy registry maintained by the manufacturer and including nearly 800
first-trimester exposures (Goldstein et al. 1997). However, the lost-to-follow-up percentage in that
study was nearly 40% and may have biased the results. A large register-based study with exposure
data collected prospectively to outcome did not reveal an increased risk of major malformations
among infants exposed to SSRIs in the first trimester (Ericson et al. 1999). The majority of
exposures were for citalopram (375 pregnant women). However, pregnancy terminations due to fetal
malformation were not included (Ericson et al. 1999). Data evaluating the safety of the other SSRIs
are less abundant, but no increased risk of major malformations has thus far emerged (Kulin et al.
1998; Chambers et al. 1999; Diav-Citrin et al 2002). Data on studies assessing SSRI safety during
pregnancy are summarized in Table 4.
2. 3. 3. Preterm birth and low birth weight
Two studies based on relatively small numbers of subjects have suggested an increased risk of
preterm birth (<37 gestational weeks) (Chambers et al.1996; Costei et al. 2002) or birth at or below
36 gestational weeks (Simon et al. 2002) in women using SSRIs during pregnancy (Table 4). A
cohort study with 531 women exposed to SSRIs found that preterm birth was more common in the
exposed cohort but also in the cohort using other antidepressants, when compared with the
population-based control cohort (Ericson et al. 1999). Data were based on confirmed first, or early
second-trimester exposure. A correlation between exposure to SSRIs and low birth weight (< 2500
g) has been proposed (Chambers et al. 1996). However, because of the small subject pool and the
methodological limitations regarding the control cohort, no definitive conclusions can be made.
2. 3. 4. Neonatal complications
Several case reports and case series have described neonatal adverse events after prenatal SSRI
exposure (Dahl et al.1997; Mohan and Moore 2000; Nordeng et al. 2001b; Stiskal et al. 2001).
Typical symptoms include irritability, jitteriness, increased muscle tone and feeding problems and,
less frequently, more severe symptoms manifesting as convulsions (Mohan and Moore 2000). The
symptoms may be caused either by abrupt drug withdrawal or by a toxic serotonergic effect on the
newborn (Isbister et al. 2001). Two controlled studies with small numbers of subjects found that
admittance to special care nursery was more common in infants exposed late in pregnancy than in
controls (Chambers et al. 1996; Cohen et al. 2000). In addition, in a prospective cohort study,
neonatal complications necessitating intensive care treatment were observed in 12 of 55 new-borns
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exposed to paroxetine during the third trimester, compared with only three of 54 infants in the
control group (Costei et al. 2002).
2. 3. 5. Long-term neurodevelopment
Major concerns of prenatal exposure to SSRI drugs include neonatal neurologic symptoms and
possible adverse effects on the developing central nervous system. No conclusive evidence of
increased risk of adverse long-term effects exists at present. Two studies assessing
neurodevelopment in pre-school and school-age children and with partially overlapping study
subjects did not find differences in global intelligence quotient (IQ) or language or behavioural
development compared with non-exposed controls, or with children exposed to tricyclic
antidepressants (Nulman et al. 1997, 2002). Furthermore, normal neurodevelopment was observed
in a one-year follow-up of 11 infants exposed to citalopram during pregnancy in a prospective,
controlled study (Heikkinen et al. 2002). Longer-term outcome was not, however, assessed.
2. 4. Risks associated with valproic acid use during pregnancy
2. 4. 1. Epilepsy and pregnancy
The population prevalence of epilepsy in Finland is 0.7% (The Social Insurance Institution in
Finland KELA 2005) and similar figures have been reported in other countries (Bell and Sander
2001). The use of major anti-epileptic drugs (valproate, carbamazepine, phenytoin and
phenobarbital) during pregnancy is associated with a two- to threefold increase in congenital
malformations in the offspring (Lindhout et al. 1992; Yerby 1993). Studies involving women with a
seizure history but no anti-epileptic drug treatment indicate that the risk is associated with anti-
epileptic drug use rather than epilepsy itself or type of epilepsy (Jick and Terris 1997; Holmes et al.
2001). Anti-epileptic drugs differ in their mode of action and specificity on epilepsy type. Valproic
acid is mainly used for generalized tonic-clonic seizures and partial seizures (Brodie and Dichter
1997; Feely 1999). Convulsive seizures may harm the fetus by maternal abdominal trauma or by
reducing placental blood flow and impairing fetal oxygenation (Teramo et al. 1979; Zahn 1998).
Consequently, avoidance of seizures is important also for the well-being of the fetus.
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2. 4. 2. Risk of major malformations
An association between caudal neural tube defects (spina bifida) and fetal exposure to valproate was
observed in 1982 in a case-control study (Robert and Guibaud 1982), and has subsequently been
confirmed in cohort and other case-control studies (Omtzigt et al 1992; Samren et al. 1997, 1999;
Canger et al. 1999; Arpino et al. 2000; Rodriguez-Pinilla et al. 2000). The estimated prevalence of
spina bifida in children born after early fetal exposure to valproate is 1-2% (Lindhout and Schmidt
1986). In addition to a dose-dependent risk of major malformations with daily valproate doses above
1000 mg, an increased risk associated with polytherapy including valproate has been confirmed in
several studies (Lindhout et al. 1992; Samren et al. 1997, 1999; Kaneko et al. 1999).
Other major malformations associated with valproate exposure include cardiac defects, urogenital
malformations and skeletal and limb defects (Clayton-Smith and Donnai 1995; Arpino et al. 2000;
Rodriguez-Pinilla et al. 2000). Occurrence of a specific valproate-related syndrome in children
exposed to valproate in utero has been suggested, with characteristic facial dysmorphism, neural
tube defects, cardiac and genitourinary malformations and developmental delay (DiLiberti et al.
1984; Christianson et al. 1994; Clayton-Smith and Donnai 1995). However, many of these
malformations also occur after exposure to other anti-epileptics, thus lacking the relative specificity
that neural tube defects have to valproate (Zahn et al. 1998).
Studies assessing valproate teratogenicity have frequently been limited by the small number of
exposed pregnant women or by methodological issues concerning retrospective ascertainment of
cases. Furthermore, characteristics of the control groups have varied between studies. The most
recent epidemiological studies on valproate and malformations are summarized in Table 5.
2. 4. 3. Developmental delay
Several studies based on small numbers of cases suggest an increased risk of long-term
neurocognitive sequelae among the offspring of mothers with epilepsy and anti-epileptic drug
treatment (Granström and Gaily 1992; Scolnik et al. 1994). Psychosocial factors and seizure activity
− rather than exposure to anti-epileptic drugs − have been speculated to play an important role in
determining the level of cognitive development (Gaily et al. 1990). However, a number of case
reports and case series have indicated increased risk of developmental delay after exposure to
valproate in utero (DiLiberti et al. 1984; Clayton-Smith and Donnai 1995; Koch et al. 1996; Moore
et al. 2000; Kozma 2001). Neonatal withdrawal symptoms are common after prenatal exposure to
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valproate, and neurological symptoms observed in the newborn have been suggested to correlate
with neurological dysfunction in pre-school-age children (Koch et al. 1996). One retrospective study
comprising 400 schoolchildren assessed additional educational needs in a cohort of children of
epileptic mothers (Adab et al. 2001); additional needs were reported more often in the group of
children exposed to valproate monotherapy (n=56) than in non-exposed children (OR 3.4, 95% CI
1.63-7.10). No association was observed for exposure to carbamazepine (Adab et al. 2001).
However, factors such as parents’ socio-economic and educational status and seizure burden were
not controlled and may have biased these observations (Adab et al. 2001).
2. 4. 4. Role of folic acid
Observational studies (Smithells et al. 1983; Milunsky et al. 1989) and randomized clinical trials
(MRC Vitamin Study Research Group 1991; Czeizel and Dudas 1992; Berry et al.1999) have
confirmed a protective role of maternal folic acid supplementation against neural tube defects in the
general population. Whether the risk is reduced for epileptic women taking anti-epileptic drugs is
unclear (American Academy of Neurology 1998). Several case reports have been published of
infants born with neural tube defects after exposure to valproate despite the mother’s folic acid
supplementation (Craig et al. 1999; Duncan et al. 2001). However, a recent case-control study
suggested that folic acid supplementation in pregnant women taking anticonvulsants
(carbamazepine) may reduce the risk of neural tube defects (Hernandez-Diaz et al. 2001). In
addition to the small number of exposed cases in that study, methodological problems included bias
of recall and timing of exposure (Hernandez-Diaz et al. 2001). Animal studies suggest altered folate
metabolism in valproic acid exposed embryos (Wegner and Nau 1992). In humans, enzyme-
inducing anti-epileptics such as carbamazepine, phenytoin and phenobarbital, reduce serum or
erythrocyte folate levels, whereas no reduction has been observed even after prolonged treatment
with non-enzyme-inducing valproate (Kishi et al. 1997; Apeland et al. 2000).
Ta
bl
e 
5.
 E
pi
de
m
io
lo
gi
ca
l s
tu
di
es
 a
ss
es
si
ng
 v
al
pr
oa
te
 te
ra
to
ge
ni
ci
ty
.
C
ou
nt
ry
M
et
ho
d
S
tu
dy
pe
rio
d
N
um
be
r o
f
pr
eg
na
nc
ie
s
ex
po
se
d 
to
va
lp
ro
at
e/
ot
he
r a
nt
i-
ep
ile
pt
ic
s
P
re
va
le
nc
e 
of
m
aj
or
m
al
fo
rm
at
io
ns
in
 v
al
pr
oa
te
-
ex
po
se
d
pr
eg
na
nc
ie
s
(%
)
 R
el
at
iv
e 
ris
k
(9
5%
 C
I)
A
dd
iti
on
al
 fi
nd
in
gs
 a
nd
 c
om
m
en
ts
R
ef
er
en
ce
S
ev
er
al
co
un
tri
es
P
ro
sp
ec
tiv
e
P
oo
le
d 
da
ta
 fr
om
 fi
ve
st
ud
ie
s
N
on
-e
pi
le
pt
ic
 c
on
tro
l
gr
ou
p
19
71
-1
99
0
18
4/
12
21
8.
7
4.
9 
(1
.6
-1
5.
0)
 a
In
cr
ea
se
d 
ris
k 
w
ith
 V
P
A
 d
os
es
 a
bo
ve
 1
00
0m
g
In
cr
ea
se
d 
ris
k 
w
ith
 p
ol
yt
he
ra
py
 in
cl
ud
in
g 
V
P
A
P
re
gn
an
cy
 te
rm
in
at
io
ns
 d
ue
 to
 m
aj
or
 m
al
fo
rm
at
io
n
in
cl
ud
ed
 o
nl
y 
in
 d
at
a 
fro
m
 2
 c
en
tre
s
S
am
re
n 
et
 a
l.
19
97
Th
e
N
et
he
rla
nd
s
R
et
ro
sp
ec
tiv
e
N
on
-e
pi
le
pt
ic
 c
on
tro
l
gr
ou
p
19
72
-1
99
4
15
8/
14
11
5.
7
4.
1 
(1
.9
-8
.8
)
In
cr
ea
se
d 
ris
k 
w
ith
 V
P
A
 d
os
es
 a
bo
ve
 1
00
0m
g
In
cr
ea
se
d 
ris
k 
w
ith
 p
ol
yt
he
ra
py
 in
cl
ud
in
g 
V
P
A
P
re
gn
an
cy
 te
rm
in
at
io
ns
 d
ue
 to
 m
aj
or
 m
al
fo
rm
at
io
n
in
cl
ud
ed
S
am
re
n 
et
 a
l .
19
99
S
ev
er
al
co
un
tri
es
(J
ap
an
,
Ita
ly
,
C
an
ad
a)
P
ro
sp
ec
tiv
e
19
78
-1
99
1
16
7/
98
3
11
.1
N
o 
co
nt
ro
l g
ro
up
In
cr
ea
se
d 
ris
k 
w
ith
 V
P
A
 d
os
es
 a
bo
ve
 1
00
0m
g/
da
y
In
cr
ea
se
d 
ris
k 
w
ith
 p
ol
yt
he
ra
py
 in
cl
ud
in
g 
V
P
A
K
an
ek
o 
et
 a
l .
19
99
Ita
ly
P
ro
sp
ec
tiv
e
19
77
-1
99
6
44
/ 5
17
15
.9
N
o 
co
nt
ro
l g
ro
up
Pr
eg
na
nc
y 
te
rm
in
at
io
ns
 d
ue
 to
 m
aj
or
 m
al
fo
rm
at
io
ns
in
cl
ud
ed
C
an
ge
r e
t a
l.
19
99
a 
 R
el
at
iv
e 
ris
k 
de
riv
ed
 fr
om
 a
 p
oo
le
d 
an
al
ys
is
 o
f 2
1 
va
lp
ro
at
e-
ex
po
se
d 
ch
ild
re
n 
co
m
pa
re
d 
w
ith
 n
on
-e
xp
os
ed
 c
on
tro
ls
30
2. 4. 5. Genetic susceptibility
Why the majority of children born to mothers using valproate during pregnancy are born healthy
while others are severely handicapped is unknown. Genetic differences in maternal folic acid
metabolism may increase the risk of fetal adverse effects associated with maternal anticonvulsant
treatment (Dean et al. 1999). Several reports of sibling pairs with developmental defects consistent
with valproate embryopathy are available in the literature (Di Liberti et al. 1984; Winter et al. 1987;
Christianson et al. 1994; Espinasse et al. 1996; Janas et al. 1998; Kozma 2001), suggesting
genetically determined susceptibility to valproate teratogenicity.
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3. AIMS OF THE STUDY
The purpose of this research project was to study, mainly by using nationwide registers, use of
prescription drugs during pregnancy, and possible fetal risks associated with gestational use of
drugs.
Specific aims were:
1. To investigate the use of prescription drugs, irrespective of their teratogenic potential, in
pregnant women.
2. To evaluate potential risks related to drug use during pregnancy by using drug classifications for
safety during pregnancy.
3. To assess fetal and newborn risks related to prenatal exposure to selective serotonin reuptake
inhibitors.
4. To describe and determine the aetiology of developmental defects and overlapping multiple
malformations in three sets of siblings exposed to valproic acid in utero.
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4. MATERIALS AND METHODS
4. 1. Definitions
4. 1. 1. Major malformations
The National Register of Congenital Malformations defines a major congenital malformation as a
significant congenital structural anomaly, chromosomal defect or congenital hypothyroidism, using
the exclusion list of minor congenital anomalies as specified in the European Surveillance of
Congenital Anomalies (EUROCAT) definitions (EUROCAT 2005; National Research and
Development Centre for Welfare and Health STAKES 2005).
4. 1. 2. Preterm birth
Preterm birth is defined as birth ending before 37 gestational weeks.
4. 1. 3. Small for gestational age
Small for gestational age is defined as birth weight of more than 2 standard deviations (SD) below
the sex- and length-of-gestation-specific national standards (Pihkala et al. 1989).
4. 1. 4. Low birth weight
Low birth weight is defined as birth weight below 2500 g.
4. 2. Use of prescription drugs during pregnancy (Studies I and II)
4. 2. 1. Register data
The majority of the data in Studies I and II were derived from three nationwide registers (Tables 6
and 7).
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Table 6. Summary of study materials and methods.
Study Materials and methods Focus Number
included in the
study
I, II Linkage of
Maternal Grants Register
Finnish Population Register
Drug Reimbursement Register
(including the Special Refund Register)
Use of prescription drugs during
pregnancy
Prescription of hazardous drugs
during pregnancy
43 470 cases
43 470 controls
III Data used in the study derived from a national
joint project, linking the
Medical Birth Register
National Register of Congenital Malfomations
National Register of Induced Abortions
Finnish Cause-of-Death Statistics
Drug Reimbursement Register
(including the Special Refund Register)
Safety of selective serotonin
reuptake inhibitors during
pregnancy
1782 cases
1782 controls
IV Evaluation of families and medical records Aetiology of overlapping multiple
malformations observed in all
siblings
Three families
with seven
children
The Maternal Grants Register, maintained by the Social Insurance Institution of Finland
(Kansaneläkelaitos, KELA), contains data on all women who have applied for maternal grants.
Grants are provided when the mother has visited a maternity clinic before the end of the fourth
month of pregnancy. Data were collected on all women applying for maternal grants in 1999. To
rule out the influence of previous pregnancies or lactation on practice of drug use, women who had
applied for maternity grants during the 24 months preceding the beginning of the pregnancy now
studied were excluded; 43 470 pregnant women were thus included. The beginning of the first
trimester was calculated by subtracting 40 weeks from the estimated delivery date recorded in the
register data. After the child is born, the date of birth is added to the register, marking the end of
pregnancy.
Controls were collected from the Finnish Population Register. For each pregnant woman, one
female control was randomly selected from women matched by age and hospital district, who had
not applied for a maternity grant during the period from 24 months before her case’s pregnancy to
the end of the year 2000.
The Drug Prescription Register maintained by KELA comprises data on 97%-98% of all reimbursed
prescriptions (Finnish Statistics on Medicines 1999, 2003) (Table 7). In Finland, prescription-only
medicines deemed necessary for the treatment of an illness are reimbursed under the Health
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Insurance Scheme. Some OTC drugs are also reimbursable when prescribed by a physician. The
Prescription Register contains a special code for specially refunded drug purchases. Patients with
specified chronic diseases (about 50 diseases total) are entitled to special refunds for drug treatment
costs. Every person entitled to special refunds is recorded in the Special Refund Register, KELA
(Finnish Statistics on Medicines 1999). Drug purchases were recorded using the date of purchase,
and drugs were coded according to the Anatomic Therapeutic Chemical (ATC) classification
system, year 2000 (Finnish Statistics on Medicines 1999; ATC 2000).
Table 7. Data quality and coverage of the registers used in Studies I-III.
Register Quality or coverage of data Reference
Maternal Grants Register All pregnant women applying for
maternal grants
Statistical Yearbook of the Social
Insurance Institution, Finland 2000
Finnish Population Register All Finnish citizens and those with
permanent residence in Finland
Population Register Centre 2005
Drug Reimbursement Register 97-98% coverage of all reimbursed
prescriptions
Finnish Statistics on Medicines
1999, 2003
Medical Birth Register Coverage close to 100%
Data quality good
Teperi 1993; Gissler et al. 1995
National Register of Congenital
Malformations
Data quality considered good STAKES 2005
National Register of Induced
Abortions
Coverage close to 100% Gissler et al. 1996
Cause-of-Death Statistics Finland Covers all deaths in Finland Statistics Finland 2005
4. 2. 2. Study design
The linkage of all three registers was done using the unique identification number (coded in a
concealed form for study purposes) assigned to all Finnish citizens and those with permanent
residence in Finland. Claims data of the study population (cases and non-pregnant controls) were
analysed in time periods of three months before pregnancy, during pregnancy (divided into three
trimesters; weeks 0-12, 13-26 and 27 onwards) and three months post-partum.
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4. 2. 2. 1. Categorization of drugs according to risk classification during pregnancy
Each fifth-level ATC code was linked to the corresponding pregnancy safety code using primarily
the Swedish classification (FASS 1999, 2000). If there was no FASS categorization for a drug, the
Australian classification (ADEC 1996) was used, and when neither existed, the American
classification (FDA) was used (Briggs et al. 2002). Drugs were grouped as ‘probably safe’ (FASS
and ADEC gategories A, B1 and B2, and FDA categories A and B), ‘potentially harmful’ (FASS
and ADEC categories B3 and C, and FDA category C) and ‘clearly harmful’ (FASS category D, and
ADEC and FDA categories D and X) (Table 2).
4.3. Risks associated with the selective serotonin reuptake inhibitors during pregnancy
(Study III)
4. 3. 1. Register data
The majority of the data in Study III were derived from five nationwide registers (Tables 6 and 7).
Data were derived from a national joint project in Finland, established by three governmental
organizations (STAKES, KELA and the Finnish National Agency for Medicines) for continuing
surveillance of drug-related safety during pregnancy. In the project, the following registers have
been linked by the unique identification number assigned to all citizens.
4. 3.1.1. Medical Birth Register
The Medical Birth Register collects maternal background data, maternal pregnancy-related medical
data, delivery data (live births and stillbirths) and neonatal outcome data, including malformations,
until the age of 7 days. All births of infants or fetuses with gestational age of at least 22 weeks or
birth weight of 500 g or more are included in the register. Data for the register are collected from all
maternity hospitals, and in the case of home births, from the assisting midwife or physician. The
register data are forwarded to STAKES and missing data are supplemented by information from
birth and death certificates.
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4. 3. 1. 2. National Register of Congenital Malformations
The National Register of Congenital Malformations defines a major congenital anomaly as a
significant congenital structural anomaly, chromosomal defect or congenital hypothyroidism, using
the European Surveillance of Congenital Anomalies (EUROCAT) exclusion list of minor anomalies,
as specified in the EUROCAT definitions (EUROCAT 2005; STAKES 2005). The registry collects
information from the whole of Finland on all newborn infants with a birth defect, using several data
sources (STAKES 2005). In case of a malformation, the delivery units are obliged to complete and
forward a special data collection form to the Malformation Register. Data on diagnosis are also
collected and confirmed from the Medical Birth Register, the Hospital Discharge Register and the
Cause-of-Death Register and from cytogenetic laboratories until the age of one year (STAKES
2005). In addition to maternity hospitals, health care professionals in outpatient clinics, such as child
welfare clinics, may provide cases that have been detected after discharge from the delivery unit to
the register. All pregnancy terminations due to fetal malformation are also recorded in the register
(Table 7).
4. 3. 1. 3. National Register of Induced Abortions
According to the national legislation in Finland, termination of pregnancy is allowed until the end of
the 20th gestational week for social reasons, and until the end of the 24th gestational week if a
serious fetal malformation has been detected. Notification of pregnancy termination must be sent to
the registry within one month after the termination. The register covers more than 99% of induced
abortions registered in the hospital records (Gissler et al. 1996) (Table 7).
4. 3. 1. 4. Drug Reimbursement Register
The Drug Reimbursement Register contains data on 97-98% of reimbursed prescription drug
purchases, and data on chronic illnesses requiring continuous drug treatment (Finnish Statistics on
Medicines 1999, 2003) (Table 7).
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4. 3. 1. 5. Cause-of-Death Statistics
The Cause-of-Death Statistics complied by Statistics Finland includes information on all postnatal
mortalities (Table 7).
4. 3. 2. Defining length of gestation and pregnancy trimesters in the national project database
The estimated length of gestation at delivery − based on the last menstrual period and ultrasound
examination − is recorded in the Medical Birth Register. In the national joint project, the beginning
of pregnancy has been defined by subtracting the number of days corresponding to gestation length
from the date of birth. In the combined database, data on drug purchases have been collected during
preconception (three months before pregnancy), each pregnancy trimester and three months
postpartum. Pregnancy trimesters have been defined as 0-12 weeks (first trimester), 13-26 weeks
(second trimester) and from week 27 onwards (third trimester). A total of 405 892 anonymous
mother - child/ fetus- pairs have been registered in the database during the period of 1996-2001.
4. 3. 3. Study design
The study material was derived from the joint research project database described in ‘Materials and
Methods’ 4.3.1. and covers the years 1996-2001. All data in the research register are anonymous.
Cases were defined as women who made at least one purchase of a SSRI drug (defined by the fourth
level ATC code) from one month preceding pregnancy to the day when pregnancy ended
(n=2077). Only singleton pregnancies were included in the study. Women with chronic illnesses
requiring continuous medication (e.g. hypertension, epilepsy, psychosis) were excluded from the
analysis (n=273). Another 22 cases were excluded because their matched pair in the control group
had a chronic illness. After exclusion, a total of 1782 cases were remained.
Controls were women with no reimbursed drug purchases during the time period from one month
before pregnancy to the end of pregnancy. They were first matched with cases by year of pregnancy
ending, age, parity (no previous deliveries or one or more previous deliveries), geographical area
(university hospital district), and social status. Matching was then done on a one-to-one basis by
randomly selecting one control for each case from the case-specific matched control pool.
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Low birth weight was defined as birth weight below 2500 g and was considered only in the analysis
of birth register cases. Small for gestational age was defined as birth weight of more than 2 SD
below the sex- and length-of-gestation-specific national standards (Pihkala et al. 1989) and was
considered only in the analysis for birth register cases. In the Medical Birth Register, only 1-minute
Apgar score is recorded. A low Apgar score was defined as a score < 7. The social class of the
mother is recorded in the Medical Birth Register in a form modified from the coding system used by
Statistics Finland (Statistics Finland 2005). In the study, a crude social distinction was used by
grouping upper officials in one category and lower officials, workers, students and housewives in
another category.
The study protocol was approved by the national health authorities, STAKES, and the Finnish Data
Protection Authority in conjunction with establishment of the joint research project.
4. 4. Valproate embryopathy (Study IV)
In Study IV, three families were evaluated at a genetics clinic to determine the aetiology of multiple
malformations and the developmental deficit among the siblings. In addition to clinical evaluation of
the children and their parents, medical records of the children and their mothers were reviewed.
4. 5. Statistics (Studies I-III)
In Study I, pregnant women served as their own controls when assessing changes in the drug-
purchasing pattern during each trimester, and they were also compared with matched controls. Odds
ratios (ORs) and 95% confidence intervals (CIs) were calculated by using Chi square cross-
tabulation.
In Study II, changes in the drug-purchasing pattern between different trimesters were calculated by
using the McNemar test (two-sided) on dichotomic variables (use or no use) for a time-dependent
association. ORs and 95% CIs were calculated by cross-tabulation using the Chi square distribution.
These tests were also used when comparing pregnant women with non-pregnant controls. Data were
analysed with SPSS 8.0 for Windows.
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In Study III, the McNemar test for categorical variables and paired t-tests for continuous variables
were used in comparisons between one-to-one matched case-control pairs. In comparisons between
different subgroups of cases and all controls, or cases with only first-trimester purchase(s),
univariable analysis to study differences between proportions was performed using Chi square test
or Fischer’s exact test for dichotomous variables and t-test for continuous variables (all two-tailed).
Variables found to differ between the study and control groups (P<0.1), and those that could be
expected to confound the association between other independent variables and dependent variables,
were included in the multivariable analysis. Logistic regression analysis was carried out applying
major malformations, low Apgar score, treatment in special or intensive care unit, low birth weight
and small for gestational age as dependent outcome variables. Independent variables in the model
were purchase(s) of SSRIs, social status, smoking, artificial reproductive techniques (ART),
previous deliveries, age and other purchased medications. All variables were entered
simultaneously. Logistic regression analysis was performed between different subgroups of cases or
between subgroups of cases and all controls. Crude and adjusted ORs and their 95% CIs were
calculated. The statistical analyses were performed using SAS version 8.2 statistical software.
Statistical significance was set at P < 0.05 (two-tailed).
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5. RESULTS AND DISCUSSION
5. 1. Use of prescription drugs during pregnancy (Studies I and II)
5. 1. 1. Reimbursements during pregnancy and lactation (Study I)
Mean age of the 43 470 pregnant women and controls was 27.9 (range 15-50) years and mean length
of gestation was 39.3 (range 22-44) weeks. The prevalence of chronic diseases entitling patients to
special refunds of medicine costs was generally higher among the controls than in the pregnant
women, with the exception of astma and thyroid insufficiency, which were equally common in both
cohorts (Table 8).
During the period corresponding to pregnancy 20 083 pregnant women (46.2%) versus 23 985
controls (55.2%) purchased one or more drugs (OR 0.7, 95% CI 0.6-0.7). The mean number of
different drugs bought during pregnancy was 2.1 in the pregnant cohort and 2.8 in the control
cohort. Of the pregnant women, 5508 (12.7%) purchased three or more different drugs versus
10 012 (23.0%) controls (OR 0.5, 95% CI 0.5-0.5); this difference was statistically significant
during all stages corresponding to pregnancy trimesters and three months post-partum. The most
frequently purchased drugs during pregnancy were antibacterials for systemic use (ATC J01; 24.1%
of pregnant women vs. 27.3% of controls), which were purchased by 9.6% of pregnant women
during the first trimester. Gynecological anti-infectives were the second most frequently purchased
drugs during pregnancy (ATC G01; 8.3% of pregnant women vs. 1.5% of controls). These drugs
were purchased less often by controls than by pregnant women throughout pregnancy.
The use of overall prescription drugs during pregnancy, and the mean number of different drugs per
user, were similar to that observed in another Scandinavian population-based study (Olesen et al.
1999a). Much higher numbers were reported in a study from France (Lacroix et al. 2000). In that
study, 99% of pregnant women used one or more prescribed drugs, and the mean number of
different drugs taken was 13.6 (Lacroix et al. 2000). The diverging observations reflect different
drug-prescribing patterns between countries.
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Table 8. Number and percentage of pregnant women and non-pregnant controls (43 470 each)
entitled to special reimbursement of medicines for certain chronic diseases at the end of 1998.
Diagnosis Pregnant women
n (%)
Controls
n (%)
Odds Ratio
(95% CI)
Asthma and similar obstructive
pulmonary diseases
1144 (2.6) 1113 (2.6) 1.0 (0.9 -1.1)
Thyroid insufficiency 357 (0.8) 316 (0.7) 1.1 (1.0 -1.3)
Epilepsy 309 (0.7) 531 (1.2) 0.6 (0.5 -0.7)
Rheumatoid arthritis and comparable
diseases
231 (0.5) 300 (0.7) 0.8 (0.6 -0.9)
Diabetes mellitus 208 (0.5) 298 (0.7) 0.7 (0.6 -0.8)
Hypertension 191 (0.4)  285 (0.7) 0.7 (0.6 -0.8)
Ulcerative colitis and Crohn´s disease 163 (0.4) 212 (0.5) 0.8 (0.6 -0.9)
Severe psychotic and other severe
mental disorders
89 (0.2) 427 (1.0) 0.2 (0.2 -0.3)
The use of systemic antibacterials has been similar to our observations in several studies (Olesen et
al. 1999a; Andrade et al. 2004; Schirm et al. 2004). However, in a French study covering a cohort of
1000 women, more than 50% received a prescription for antimicrobial agents during pregnancy
(Lacroix et al. 2000). Although many of the older preparations in this group are considered safe
during pregnancy, recent data suggest that trimethoprim exposure in early pregnancy may be
associated with an increased teratogenic risk (Hernandez-Diaz et al. 2000, 2001). Several of the
gynecological anti-infectives in Finland are OTC drugs and their use may have been even more
extensive than seen in our study, which included only prescription drugs. Much higher percentages
have been reported in studies from France and Germany (Lacroix et al. 2000; Egen-Lappe and
Hasford 2004). Persistent bacterial vaginosis is a known risk factor for preterm delivery and,
consequently, infant morbidity and mortality. However, routine screening and treatment have not
proven beneficial (Kekki et al. 2001).
Antidepressants were purchased by fewer pregnant women than by controls in all time periods
concerned, but serious psychiatric disorders were also less common in the pregnant cohort (Table 8).
Of the pregnant women, 1.4% purchased antidepressants during the preconception period, the
proportion declining to 0.7% in the first trimester and to 0.3% in the third trimester, and increasing
again during lactation (to 0.7%). A statistically significant reduction was also observed in the
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number of women purchasing several other drug groups during the first trimester as compared with
three months’ preconception. These included drugs for peptic ulcer (ATC A02; 0.9% vs. 0.6%), sex
hormones and modulators of the genital system (G03; 5.4% vs. 4.2%), systemic antimicrobials (J01;
12.1% vs. 9.6%) , systemic antimycotics (J02; 1.9% vs. 0.7%), anti-inflammatory drugs (M01; 5.1%
vs. 1.9%) and antipsychotics, anxiolytes, hypnotics and sedatives (N05; 1.1% vs. 0.9%), nasal
preparations (R01; 3.1% vs. 2.0%), cough and cold preparations (R05; 2.7% vs. 1.5%) and systemic
antihistamines (R06; 1.9% vs. 0.8%). Fewer pregnant women than non-pregnant controls purchased
these drugs during each trimester and the post-partum period, except for sex hormones and
modulators of the genital system which were purchased by a larger number of pregnant women
during the first trimester (OR 1.1, 95% CI 1.0-1.2), and antimicrobials which were purchased more
abundantly by mothers than by controls during lactation (OR 2.3, 95% CI 2.2-2.4).
A recent study from the US based on drug-dispensing data reported that altogether 3.6% of women
used antidepressants during pregnancy, 2.7% of them in the first trimester, showing a declining
trend with advancing pregnancy (Andrade et al. 2004). Furthermore, another recent study from the
US based on interviews reported that approximately 1% of pregnant women had used SSRI drugs
during pregnancy (Refuerzo et al. 2005). By contrast, in a study from Europe, less than 0.3% of
women interviewed during pregnancy reported using antidepressants (Headley et al. 2004). Besides
cultural differences, one possible explanation is that women are unwilling to report the use of
psychotropic drugs.
Treatment of chronic illnesses requiring drug therapy continued during pregnancy. Chronic asthma
was diagnosed at similar rates in pregnant women and in non-pregnant controls (Table 8), and the
number of women receiving asthma medications throughout the study period corresponding to
pregnancy did not differ between the two cohorts. A small decline in pregnant users of anti-
asthmatic drugs occurred in the first trimester, but the number increased again in the second
trimester (Figure 1). The frequency of epilepsy treatment was similar during the preconception
period, all stages of pregnancy, and lactation (Figure 1). Insulin was responsible for the increase in
drug reimbursements for diabetes during pregnancy.
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Figure 1. Percentage of pregnant women and non-pregnant controls (43 470 each) purchasing drugs for selected
chronic diseases. Each second-level ATC code was recorded only once per person. Time periods: pre= preconception,
1st= first trimester, 2nd= second trimester, 3rd= third trimester.
Relatively few other studies have investigated the pattern of drug use for treating chronic illnesses,
such as asthma, epilepsy or diabetes, during pregnancy. Drug treatment of asthma remained fairly
constant throughout pregnancy in a register-based Danish study (Olesen et al. 1999b), consistent
with our findings. Although large epidemiological studies are scant, existing data do not indicate a
major risk for congenital malformations or other adverse outcomes with maternal exposure to
commonly used asthma medications (Källen et al. 1999; Jadad et al. 2000; Gluck and Gluck 2005).
Furthermore, untreated asthma requiring drug treatment presents a definite risk to the pregnancy and
the fetus (Namazy and Schatz 2004). As in our study, anti-epileptic drugs were prescribed in a
constant manner throughout pregnancy in one interview-based (Rubin et al. 1993) and three register-
based (Olesen et al. 1999b; Andrade et al. 2004; Egen-Lappe and Hasford 2004) studies. All
traditionally used anti-epileptics are known teratogens, but adequate treatment of epilepsy presents a
smaller risk to the fetus than does untreated epilepsy (Yerby 2000). In the present study the use of
insulin increased throughout pregnancy. Similar results were reported in another study based on
prescription data (Egen-Lappe and Hasford 2004). This is in accordance with generally accepted
guidelines to use insulin instead of oral antidiabetics during pregnancy, and indicates rational
prescribing of drugs.
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5. 1. 2. Reimbursements according to drug safety categorization (Study II)
A total of 562 different active substances according to the ATC code were recorded in the two
cohorts, and a pregnancy safety categorization was identified for 528 drugs (94%). The majority of
drugs were categorized according to the FASS classification (76.2% of all different active
substances recorded), and the rest were categorized according to the ADEC classification (8.6%)
and the FDA classification (9.1%).
During overall pregnancy, 8853 women (20.4 %) purchased at least one drug that was classified as
potentially harmful, versus 15 562 of non-pregnant controls (35.8%) (Figure 2). The number of
pregnant women purchasing potentially harmful drugs during the first trimester was lower than
during the preconception period (11.2% vs. 17.9%; OR 0.6, 95% CI 0.6-0.6; P<0.05) (Figure 3a).
The decline continued from the first to the second trimester (OR 0.7, 95% CI 0.7-0.7; P<0.05) but no
difference was present between the second and third trimesters (P=0.2) (Figure 3a). The majority of
potentially harmful drugs purchased in the preconception period were non-steroidal anti-
inflammatory drugs (NSAIDs) and drugs for infertility treatment. In the first trimester,
pivmecillinam was the most frequently purchased drug classified as potentially harmful (1.4% of all
pregnant women), followed by chorionic gonadotropin (0.8%) and clomiphene (0.7%). Ibuprofene,
fluconazole, and nasal fluticasone – all grouped as potentially harmful − were each purchased by
0.6% of pregnant women.
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Figure 2. Percentage of pregnant women and non-pregnant controls (43 470 each) purchasing drugs grouped as
probably safe, potentially harmful and clearly harmful during pregnancy.
Regular use of NSAIDs at the time of conception or in early pregnancy has been associated with an
increased risk of miscarriage in a carefully conducted cohort study (Li et al. 2003). Furthermore,
prostaglandin inhibition may affect fertility by interfering with normal ovarian follicular
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development and ovulation (Killick and Elstein 1987; Stone et al. 2002). The regular use of
NSAIDs should therefore be avoided already in the preconception period. Due to the register-based
design in our study, considerable overestimation of exposure to infertility drugs during
organogenesis is likely, as these drugs are used to stimulate ovulation, and consequently, exposure
occurs before pregnancy begins. Pivmecillinam is categorized as potentially harmful because of its
capacity to lower serum carnitine levels (FASS 1999). However, no adverse effects on the fetus
have been reported, and pivmecillinam is considered safe for use in pregnancy in clinical practice
(Christensen 2001). Furthermore, existing data do not indicate a major risk of congenital
malformations or other adverse outcomes with maternal exposure to commonly used allergy or
asthma medications (Kalter and Warkany 1983b; Källen et al. 1999; National Heart, Lung and
Blood Institute: National Asthma Education and Prevention Program Asthma and Pregnancy
Working Group 2005).
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Figure 3a and b. Percentage of pregnant women and non-pregnant controls (43 470 each) purchasing drugs grouped as
potentially harmful (a) and clearly harmful (b). Time periods correspond to preconception (3 months before first
trimester) and pregnancy trimesters.
One or more drugs classified as clearly harmful were purchased by 1478 women (3.4%) during
overall pregnancy, compared with 6075 non-pregnant controls (14%) (Figure 2). The number of
pregnant women purchasing clearly harmful drugs was lower during the first trimester than during
the preconception period (3.2% vs. 5.5%; OR 0.6, 95% CI 0.5-0.6; P<0.05), declining further from
the first to the second trimester (OR 0.1, 95% CI 0.1-0.2; P<0.05) (Figure 3b). No difference was
present between the second and third trimesters (P=0.9) (Figure 3b). During preconception the most
commonly purchased clearly harmful drugs were doxycycline (2.1% of all pregnant women),
follitropin alpha or beta (1.6%), estradiol (0.4%) and norethisterone (0.4%). During the first
trimester the most commonly purchased clearly harmful drugs were follitropin alpha or beta (1.4%),
doxycycline (0.6%), estradiol (0.4%), carbamazepine (0.2%), menotropin (0.2%) and valproate
(0.1%). The use of carbamazepine and valproate remained constant throughout pregnancy. Twenty-
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one women purchased tetracyclines in the second trimester. Three women purchased isotretinoin in
the preconception period, and one during each pregnancy trimester.
As discussed previously, infertility treatments are used to induce ovulation and are therefore used
prior to conception, and consequently, are not likely to affect embryonic development. Tetracyclines
do not increase risk of major malformations when used in early pregnancy, but they may cause
discoloration of deciduous teeth when used after 16th week of pregnancy (Cohlan 1977; Webster
and Freeman 2003). Isotretinoin is a major teratogen, with first-trimester exposure leading to a 40%
risk of abortion and a 25-30% risk of major malformations in newborns (Lammer et al.1988). An
increased risk of developmental delay even in the absence of detectable major malformations has
also been observed (Adams and Lammer 1993; Coberly et al. 1996; Kalter 2003). Furthermore, due
to the relatively long half-life of isotretinoin, exposure shortly before or at conception may increase
risk as well (Nulman et al. 1998).
A Danish study based on registers and FASS categorization of drugs reported that 18% of pregnant
women were exposed to potentially or clearly harmful drugs during pregnancy (Olesen et al.1999b).
In that study, the proportion of prescriptions for drugs classified as potentially harmful decreased
during pregnancy, similarly to our findings. A French study based on prescriptions found that 59%
of pregnant women purchased drugs known to be harmful according to the FDA categorization and
1.6% purchased drugs that were absolutely contraindicated (Lacroix et al. 2000). A register-based
study from the US and covering over 150 000 deliveries found that 1.1% of pregnant women
purchased drugs categorized as contraindicated during pregnancy; however, when female
reproductive hormones were excluded, the proportion declined to 0.1% (Andrade et al. 2004).
Another register-based study from the US reported that 0.3% of pregnant women filled prescriptions
for contraindicated drugs during the first trimester (Cooper et al. 2004). Moreover, the FDA
classification classifies some benzodiazepines as contraindicated, even though at present these drugs
are not considered teratogenic (McElhatton 1994; Ornoy et al. 1998; Webster and Freeman 2003). A
Dutch study based on pharmacy record data and the Australian risk classification disclosed that 10%
of prescriptions for pregnant women belonged to the potentially harmful group (including
recognized teratogens), compared with 49% of prescriptions for non-pregnant women (Schirm et al.
2004). The majority of prescriptions for pregnant women considered potentially harmful in that
study were for psycholeptics (N05), psychoanaleptics (N06) and NSAIDs (M01) (Schirm et al.
2004).
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5. 1. 2. 1. Polytherapy
A total of 107 (0.2%) pregnant women purchased 10 or more different drugs during the period of
pregnancy (mean 12.0, range 10-28), and 29 (0.1%) purchased five or more drugs during each
trimester. In this subgroup of 107 women, drugs most frequently purchased during pregnancy
(defined by the third-level ATC code) were dermal corticosteroids (85% of pregnant women),
decongestants and other nasal preparations for topical use (74%), adrenergic inhalants (67%), other
inhaled drugs for obstructive airway diseases (63%), penicillins (62%), other beta-lactam
antibacterials (59%), gynecological anti-infectives (50%), anxiolytics (38%), corticosteroids for
systemic use (38%), antihistamines (32%), and NSAIDs (31%). Accordingly, the drug groups
responsible for multidrug use were relatively innocent. At present, no evidence exists that drugs
from any of these drug groups would pose any appreciable teratogenic risk (Koren et al. 1998;
Kalter 2003; Webster and Freeman 2003; Gilbert et al. 2005). The use of systemic corticosteroids in
certain situations is well-founded, but anxiolytics and NSAIDs are probably prescribed and used
with less well-defined indications.
The number of pregnant women purchasing two or more anti-epileptic drugs concurrently was 23
(7.4% of the 309 pregnant women with an epilepsy diagnosis) during the preconception period,
remaining essentially the same throughout the pregnancy trimesters. Among the 21 anti-epileptic
drug combinations purchased, 7 contained valproic acid and 4 included three different anti-
epileptics. Polytherapy may increase teratogenic risk considerably, and the principal goal in epilepsy
treatment during pregnancy should be monotherapy (Pennell 2003). All women with epilepsy who
are planning a pregnancy are recommended to take folic acid supplementation (Wald et al. 2001;
Yerby 2003). Because folic acid is not reimbursable in Finland, the frequency of folic acid
supplementation in this subgroup of pregnant women could not be analysed.
5. 2. Safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy (Study III)
5. 2. 1. General characteristics of the study population
Women with SSRI purchases and their matched controls numbered 1782 each. The mean age of the
women in both cohorts at delivery was 30.0 years (SD 0.7). There were more than twice as many
tobacco smokers in the cohort of women with SSRI purchases than in the cohort of controls
(P<0.0001). Similarly, pregnancy induced by artificial reproductive techniques was six times more
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common in women with SSRI purchases (P<0.0001). The mean length of gestation was shorter
(P<0.0001), and the mean birth weight slightly lower (P<0.0001) in SSRI-exposed women. The
rates of perinatal death, Caesarean section and total number of malformations in offspring of SSRI
users did not differ statistically significantly from those in the control group.
5. 2. 2. First-trimester exposure and major malformations
A total of 1398 mother-infant/fetus pairs were recorded with at least one SSRI drug purchase during
one month preceding pregnancy or in the first trimester. These mothers had 57 infants or fetuses
with major malformations, compared with 62 in the control cohort (n=1782). The difference in
malformation rate between the exposed and nonexposed cohorts was not statistically significant (P=
0.4, adjusted OR 1.0, 95% CI 0.6-1.7). Moreover, when cases with first-trimester SSRI purchase(s)
were compared to their matched controls (n=1398), the malformation rate did not differ between the
two groups (P=1.0). The occurrence of major malformations was not independently associated with
any of the confounding variables considered in the logistic model. The confounders considered in
the logistic analysis were age (<20 or >40 vs. >20 and <40), social status (low vs. high), smoking
(yes vs. no), previous pregnancies (yes vs. no) and other reimbursed medications (yes vs. no).
Citalopram was the most frequently purchased SSRI drug during the first trimester (554 women),
followed by fluoxetine (525 women). In a subgroup analysis of individual SSRIs, major
malformations were more common only in fetuses or infants of women with fluoxetine exposure in
the first trimester compared with all control women with no drug purchases (P=0.03). After
adjusting for confounders (age, smoking, low social status, parity and purchases of reimbursed drugs
other than SSRIs), the association was almost statistically significant (OR 1.7, 95% CI 0.9-3.3).
Women with fluoxetine exposure during the first trimester had 29 infants or fetuses with major
malformations (5.5%), compared with 62 out of 1782 in the control group (3.5%). There were 12
isolated cardiovascular malformations in infants of fluoxetine-exposed women; the prevalence was
thus 23 per 1000 newborns. This is nearly threefold the prevalence of cardiovascular malformations
in Finland (8 per 1000 newborns). Of the isolated cardiovascular malformations in fluoxetine-
exposed women, eight were ventricular septal defects (VSDs). In addition to isolated cardiovascular
malformations, two cardiovascular malformations were recorded in four infants with chromosomal
abnormalities (all 21 trisomies), and four cases were recorded with urinary tract malformations.
After excluding chromosomal abnormalities, there were 25 malformations in the fluoxetine-exposed
pregnancies (4.8%) and 52 in the control cohort (2.9 %).
49
Prospective studies on first-trimester fluoxetine exposure have been published without evidence of
increased risk of major malformations (Pastuszak et al. 1993; Chambers et al. 1996; Hendrick et al.
2003). However, numbers in the cohorts have been relatively small, and the samples may not have
been representative of the population overall. The fluoxetine pregnancy registry maintained by the
manufacturer reported nearly 800 first-trimester exposures with no suggestion of increased risk
(Goldstein et al. 1997). However, post-marketing surveillance data are based on spontaneous
reporting and have serious limitations due to the high percentage of cases lost to follow-up, making
definitive conclusions difficult.
Similarly to fluoxetine, previous studies have not identified an increased risk of malformations with
other SSRIs (Kulin et al. 1998; Ericson et al. 1999; Diav-Citrin et al. 2002). Quite recently,
however, two preliminary reports have suggested an association between first-trimester paroxetine
exposure and cardiovascular malformations (Diav-Citrin et al. 2005; GlaxoSmithKline Clinical Trial
Register 2005). In one of these studies, most of the cardiovascular malformations were VSDs
(GlaxoSmithKline Clinical Trial Register 2005), consistent with the malformations present in the
fluoxetine-exposed cohort in the present study. The similar pattern of malformations raises some
concerns about the teratogenic potential of these drugs.
5. 2. 3. Continuous exposure during pregnancy and small for gestational age, low birth weight
and preterm birth
While during the period covering preconception and the first trimester the total number of SSRI
users was 1398, the number of women purchasing one or more SSRI drugs during the second and
third trimesters or during each trimester was 360. Small for gestational age was more common in
infants born to mothers with continuous exposure (n=360) than in infants of mothers with no SSRI
purchases (n=1779) (P= 0.001, adjusted OR 2.4, 95% CI 1.1-5.3). To avoid possible bias related to
the underlying illness, women with continuous exposure were compared with women with only
first-trimester exposure (n=1010). A considerable difference in the frequency of small for
gestational age, reaching almost statistical significance, was found between the two groups (P=0.08,
adjusted OR 1.9, 95% CI 1.0-3.8). Mean birth weight and mean length of gestation did not differ
between the continuous-exposure group and those exposed only during the first trimester. Low birth
weight was no more common in the exposed cohort than in the non-exposed control cohort (P=0.3),
or in the cohort exposed only during the first trimester (P=1.0, adjusted OR 1.0, 95% CI 0.5-2.0).
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The results suggest but do not confirm a drug-specific risk of small for gestational age. One previous
study based on a small cohort has suggested an increased risk of small for gestational age in full-
term infants after exposure to fluoxetine in late pregnancy (Chambers et al. 1996), but in a large
register-based study no such risk was observed (Källen 2004). One previous study with a small
number of cases and no control group suggested an increased risk of low birth weight with high
doses of fluoxetine (Hendrick et al. 2003). Furthermore, a Swedish study recently reported a twofold
increase in the rate of low birth weight in infants exposed to SSRIs during the second or third
trimester compared with a population-based control cohort (Källen 2004). Those results differ from
our findings and are difficult to explain because both studies had large numbers of cases, and
confounding factors, including smoking, were controlled for. In the Swedish study, a risk of similar
magnitude was found in pregnancies with exposure to tricyclic antidepressants, suggesting a role of
residual confounding linked to the disease rather than a drug-specific effect (Källen 2004).
No increased risk of preterm birth (<37 gestational weeks) (P=0.2, adjusted OR 0.7, 95% CI 0.3-1.3)
was found, and there were no births earlier than or at 32 gestational weeks in the continuous-
exposure cohort. Three previous studies have suggested an increased risk of preterm birth in women
using SSRIs during pregnancy (Chambers et al. 1996; Simon et al. 2002; Källen 2004). The first of
these studies, a prospective cohort study based on cases collected by Teratology Information
Services, found a relative risk of 4.8 for preterm birth after fluoxetine exposure (Chambers et al.
1996). In that study, mean age of exposed mothers was higher than in the non-exposed control
group. In addition, women using antidepressants were more likely to smoke and use alcohol, both
factors which may increase the risk for preterm birth (Ohmi et al. 2002; Lemoine et al. 2003). A
controlled study based on medical records reported birth at or below 36 gestational weeks being
more common in the exposed cohort (OR 4.4) (Simon et al. 2002). However, both of these studies
were based on relatively small cohorts. A large study based on registry data and prospectively
collected interviews found a statistically significant increased risk for preterm birth after adjustment
for confounders (OR 2.0), but the same risk was observed in pregnancies exposed to tricyclic
antidepressants (Källen 2004).
5. 2. 4. Third-trimester exposure and neonatal outcome
A total of 597 women purchased SSRIs during the third trimester. Compared with those with only
first-trimester exposure, no difference was observed between these cohorts in the mode of delivery
(vaginal or Caesarean section) (P=0.6). Low Apgar score was more common in infants of women
using SSRIs in the third trimester than those exposed only in the first trimester (P=0.05, adjusted
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OR 1.6, 95% CI 1.0-2.4). Similarly, treatment in special or intensive care units was more common in
infants exposed in the third trimester (15.7% vs. 11.2%) (P=0.009), and this association remained
statistically significant after adjusting for confounding variables (OR 1.6, 95% CI 1.1-2.2).
The results are in agreement with previous studies of increased risk of neonatal problems and need
for neonatal special or intensive care unit treatment or low Apgar score (Chambers et al. 1996;
Costei et al. 2002; Laine et al. 2003; Källen 2004; Oberlander et al. 2004). The largest of these
studies, based on prospectively collected exposure data, included a total of 985 women with
antidepressant use, 558 of whom were exposed to SSRIs (Källen 2004). A twofold incresed risk of
low Apgar score was found in neonates exposed to SSRIs in utero compared with a population-
based control cohort (Källen 2004). A limitation in the study was that in nearly 40% of the exposed
women, timing of exposure could not be confirmed. Several case reports and case series have also
suggested an association between SSRI exposure in late pregnancy and neonatal respiratory
difficulties or central nervous system excitation (Mohan and Moore 2000; Nordeng et al. 2001b).
One recent case report described a neonate with severe adverse effects, including tremor and
rigidity, who was genotyped to be a poor metabolizer of CYP2D6, the enzyme responsible for
paroxetine metabolism (Laine et al. 2004). Contrary to these findings, one prospective study of 64
women using fluoxetine did not find an increased risk of any neonatal adverse effects examined,
including low Apgar score and admittance to special or intensive care unit (Suri et al. 2004). In that
study, depressive women using fuoxetine were compared with depressive women without
medication and with non-depressive controls. Only non-smoking women with neither potentially
harmful medications nor alcohol use were included in the study. No adverse effects in perinatal
outcome, including preterm birth, low birth weight or low Apgar score, were correlated with
fluoxetine exposure or to depression (Suri et al. 2004). The differing findings from previous studies
may partly be explained by differences in study populations (Suri et al. 2004).
In the present study, diagnoses for the stay at neonatal special or intensive care unit (ICD-10 in the
Birth Register) were unspecific and did not allow definite conclusions about the origin of neonatal
problems. Furthermore, no data on duration of stay in these units were available. However, drug-
induced withdrawal symptoms or drug toxicity in newborns are a likely explanation for the observed
results.
Paroxetine exposure in late pregnancy has been associated with neonatal convulsions in a database
analysis based on spontaneous reporting (Sanz et al. 2005). In the present study, treatment in special
or intensive care unit was more common in the neonates exposed in the third pregnancy trimester to
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other SSRIs than in the 64 neonates exposed to paroxetine (P=0.02); however, the numbers were too
small to draw any definitive conclusions.
5.3. Valproate embryopathy (Study IV)
Three families with altogether seven children were examined clinically, and their medical records
and photographs were carefully reviewed. The families had been referred to a genetics clinic to
determine the aetiology of similar multiple malformations and developmental deficits in the siblings.
One mother had had one generalized seizure at gestational week 36, and one mother had had two
nocturnal generalized seizures of unknown duration at weeks 11 and 14; otherwise, all pregnancies
had been uneventful. One child in each family had a normal karyotype, therefore, parental
chromosomal abnormalities as aetiological factors could be excluded. The age of the children at
assessment ranged from 13 months to 8 years.
Table 9. Signs and symptoms of fetal valproate syndrome in siblings.
Family A Family B Family CSign
Patient 1 Patient 2 a Patient 3 Patient 4 Patient 5a Patient 6 a Patient 7 a
Facial
dysmorphism
+ + + + + + +
Malformations Small
fingernails
Cleft palate
Trigono-
cephaly
Short
phalanges
Underriding
third toe
Cleft palate
Trigono-
cephaly
Multicystic
dysplasia of
kidney
Inguinal
hernias
Underriding
third toes
Proximally
placed thumbs
- Inguinal
hernias
Duplex thumb
Unilateral
kidney
agenesis
Tracheo-
malacia
Enlarged
cerebral
ventricles
Unilateral
kidney
agenesis
Severe
sensorineural
hearing loss
Developmental
delay
Moderate
(verbal,
motor)
Mild
(verbal,
motor)
Mild
(motor)
Mild
(verbal,
visuomotor)
Moderate
(verbal)
Moderate
(overall)
Mild
(motor)
a Normal karyotype
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5. 3. 1. Facial dysmorphism and other malformations
All of the children had subtle but strikingly similar typical facial dysmorphism, including medial
deficiency of the eyebrows, a broad nasal root, anteverted nares, a shallow philtrum and a long, thin
upper lip (Table 9). Furthermore, two siblings had trigonocephaly, in one case necessitating
cranioplasty at the age of 7 months, and both had a surgically corrected cleft palate (Patients 2 and
3). Four children in two families had hand and foot malformations, including an underriding third
toe with and without short phalanges (two siblings), preaxial polydactyly and small fingernails. Two
children from different families had inguinal hernias. Two siblings had unilateral renal agenesis
(Patients 6 and 7), and one child had an unilateral non-functioning kidney (Table 9).
The typical facial dysmorphism, observed in all siblings, has been described previously in several
reports (DiLiberti et al. 1984; Jäger-Roman et al. 1986; Winter et al. 1987; Ardinger et al. 1988;
Clayton-Smith and Donnai 1995; Moore et al. 2000; Kozma 2001; Dean et al. 2002; Mawer et al.
2002). These features are typical of valproate embryopathy, but are not specific, as some of them are
also seen after exposure to other anti-epileptic drugs (Moore et al. 2000). Trigonocephaly and cleft
palate are both malformations that have previously been frequently described in valproate
embryopathy (Kozma 2001; Wide et al. 2004; Vajda and Eadie 2005). Congenital limb
malformations after exposure to valproate in utero have been observed in several case reports and
case series (Winter et al. 1987; Verloes et al. 1990; Buntinx 1992; Clayton-Smith and Donnai 1995),
and an association between exposure to valproate and limb malformations has been confirmed in a
case-control study (Rodriquez-Pinilla et al. 2000). Inguinal hernia has been frequently observed in
children exposed to valproate (Jäger-Roman et al. 1986; Kozma 2001). Kidney hypoplasia has been
described in association with valproate embryopathy (Verloes et al. 1990), but neither renal agenesis
nor severe sensorineural hearing loss, diagnosed in one of the children, has been reported earlier.
5. 3. 2. Neonatal withdrawal and developmental delay
Five of the seven children had neonatal withdrawal symptoms at or shortly after birth. One infant
had convulsions necessitating drug treatment, and respiratory distress. Three infants were treated in
a ventilator after birth, and one infant experienced transient tachypnoea with rapid spontaneous
recovery. Moderate developmental delay had been confirmed in three children and mild
developmental delay in four.
54
Neonatal withdrawal symptoms or drug toxicity have been reported to be frequent after valproate
exposure in utero (Jäger-Roman et al. 1986; Koch et al. 1996; Ebbesen et al. 2000; Dean et al.
2002;  Mawer et al. 2002). The severity of the symptoms may also be related to neurological
dysfunction later in life (Koch et al. 1996; Hernandez-Diaz and de Abajo 2003).
Epilepsy might affect children’s intellectual development by the neurotoxic effect of the anti-
epileptic drug, by brain damage induced by maternal convulsions, or by hereditary causes (Gaily et
al. 1990). In our study, no deficient intelligence was reported in any of the parents. The correlation
between brief maternal convulsions − such as had been documented in two pregnancies – and
neurodevelopment is controversial (Gaily et al. 1988, 1990; LaJoie and Moshe 2004). Furthermore,
seizure history per se has not been shown to increase risk of cognitive dysfunction (Holmes et al.
2000). Several studies have suggested an increased risk of neurodevelopmental delay after exposure
to valproate in utero (Koch et al. 1996; Adab et al. 2001; Dean et al. 2002; Adab et al. 2004; Gaily
et al. 2004), but several confounding factors, including the severity of the disease and hereditary
factors, may bias these results. One retrospective study based on data gathered by sending
questionnaires to epileptic mothers found that children exposed to valproate had lower verbal
intelligence quotient (IQ) than those exposed to other anti-epileptic drugs (Adab et al. 2004).
However, the low response rate and the retrospective methodology used in that study may have
biased the results (Adab et al. 2004). Another, carefully conducted prospective cohort study found
lower verbal intelligence in valproate-exposed children than in non-exposed controls (Gaily et al.
2004). However, the results were confounded by low maternal education and polytherapy (Gaily et
al. 2004). Both studies were based on relatively small numbers of exposed subjects. Developmental
delay was observed in 28% of the 46 children exposed to valproate in utero in a retrospective,
population-based study (Dean et al. 2002). After excluding affected children with a positive family
history from the analysis, the rate of developmental delay declined but speech and language
disorders remained more frequent in the valproate-exposed cohort than in non-exposed children
(Dean et al. 2002). The results suggest that the interaction between fetal drug exposure and
hereditary susceptibility factors is important (Dean et al. 2002). This is in accordance with a recent
population-based study from Finland, in which inheritance and environmental factors were proposed
to partly explain the increased prevalence of neurocognitive symptoms in children exposed to
valproate in utero (Eriksson et al. 2005).
The characteristic facial dysmorphism may be a marker of underlying central nervous system
dysfunction and developmental problems (Mawer et al. 2002; Adab et al. 2004). Several case
reports and case series have suggested an association between autism and maternal exposure to
valproate (Williams and Hersh 1997; Moore et al. 2000; Williams et al. 2001). In animal studies,
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valproate exposure leads to a selective loss of neurons, affecting the development of motor cranial
nerve nuclei, and a similar mechanism has been hypothesized for autistic humans (Rodier et
al.1996). These observations highligt the direct neurotoxic potential of valproate.
5. 3. 3. Dose and polytherapy
In the present study, the daily dose of valproate in all pregnancies was relatively high, ranging from
1000 to 2500 mg. The dose was divided into two daily doses in four pregnancies, and in three daily
doses in three pregnancies. Maternal serum valproate levels were within the reference range in all
pregnancies. One of the children was also exposed to phenytoin in utero but only from 36 weeks
onwards. Another child was exposed to valproate and vigabatrin throughout pregnancy.
A threshold dose of 1000 mg or more predicting increased risk of major malformations has been
established in several studies (Omzigt et al. 1992; Kaneko et al. 1999; Samren et al. 1999: Mawer et
al. 2002; Perucca 2005; Vajda and Eadie 2005). As teratogenesis is a threshold phenomenon, it is
obvious that larger doses imply greater risk. However, individual hereditary factors in the mother
and the fetus may exist, and therefore, caution is warranted when drawing conclusions about risks
related to a given milligram dose.
The effect of phenytoin exposure in utero on neurodevelopment is controversial (Gaily et al. 1988;
Scolnik et al. 1994; Dean et al. 2002), but it is unlikely that a one-week treatment would have a
significant impact. Little is known about the teratogenic potential of vigabatrin because this drug is
usually administered in conjunction with other anti-epileptic drugs (McCorry et al. 2004; Hunt and
Morrow 2005). Several studies have observed an increased risk of major malformations with
polytherapy including two or more anti-epileptic drugs (Lindhout et al. 1992; Kaneko et al. 1999;
Samren et al. 1999; Kaaja et al. 2003; Pennel 2003; Wide et al. 2004).
5. 3. 4. Role of folic acid
No neural tube defects, which are among the most severe valproate-associated malformations,
occurred in our patients. Periconceptional folic acid was used in only one pregnancy.
The prevalence of neural tube defects after early intrauterine valproate exposure is 2-5%, ten- to
twentyfold that observed in the general population (Alsdorf and Wyszynski 2005). Periconceptional
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supplementation with a 4-mg daily dose of folic acid reduces the recurrence of neural tube defects
by 70% in infants of non-epileptic women (MRC Vitamin Study 1991). The effect of valproate on
human folate is controversial but even prolonged valproate treatment may not influence serum or
erythrocyte folate levels (Kishi et al. 1997; Apeland et al. 2000; Verrotti et al. 2000). Low serum
folate levels were correlated with adverse outcome in one large, prospective study on epileptic
women (Kaaja et al. 2003). At present, no conclusive evidence of the protective role of folic acid in
pregnancies exposed to anti-epileptic drugs exists (Alsdorf and Wyszynski 2005).
5. 3. 5. Hereditary susceptibility
All of our patients had developmental defects characteristic of valproate embryopathy. One sibling
in each family had a normal karyotype, therefore parental chromosomal abnormalities as
aetiological factors could be excluded. Several affected sibling pairs have been described in the
literature (Kozma 2001; Moore et al. 2000). Our seven patients with valproate embryopathy,
representing all children in three families, strongly suggest the significance of hereditary factors in
development of the embryopathy.
5. 3. 6. General aspects
Valproic acid crosses the placenta and higher concentrations have been observed in the fetus than in
the mother (Nau et al. 1981; Kaneko et al. 1983; Nau et al. 1984). The teratogenicity of valproic
acid has been established in several case-control and cohort studies (Omtzigt et al. 1992; Kaneko et
al. 1999; Samren et al. 1999; Arpino et al. 2000; Rodriquez-Pinilla et al. 2000; Kaaja et al. 2003;
Wide et al. 2004; Artama et al. 2005) and recently also in studies based on data from national and
international pregnancy and epilepsy register databases (Vajda and Eadie 2005; Wyszynski et al.
2005).The risk of a major congenital malformation after exposure to valproate in early pregnancy is
estimated to be two- to fourfold higher than that in the general population, but even higher numbers
have been proposed (Alsdorf and Wyszynski 2005). In addition, minor malformations, including
facial dysmorphism and digital anomalies, are frequently observed (Jäger-Roman et al. 1986;
Clayton-Smith and Donnai 1995; Alsdorf and Wyszynski 2005). Some of the birth defects produced
by valproate, such as caudal neural tube defects (spina bifida), characteristic facial features and
radial ray defects, are more specific than those defects related to maternal use of other anti-epileptic
drugs, suggesting that the teratogenic influence occurs along specific developmental pathways
(Moore et al. 2000; Barrett and Richens 2003; Alsdorf and Wyszynski 2005). In general, only a
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small proportion of exposed children are affected (Hunt and Morrow 2005). The mechanisms
underlying susceptibility have not been established. In one study, maternal mutation in the
methylenetetrahydrofolate reductase (MTHFR) was associated with adverse outcome in pregnancies
of epileptic mothers using anticonvulsants (Dean et al. 1999). Generally, the 677 C > T mutation is
associated with decreased activity of the MTHFR enzyme and has been suggested to be a genetic
risk factor for neural tube defects, although the findings are controversial (Finnell et al. 2000, 2003).
In another study, autoantibodies to folate receptors were found more frequently in sera of women
with offspring with neural tube defects than in controls (Rothenberg et al. 2004). By binding to
folate receptors, these autoantibodies may interfere with cellular uptake of folate (Rothenberg et al.
2004). These results are interesting given that neural tube defects are characteristic of valproate
embryopathy. However, at present, the clinical relevance of these findings in pregnant women
treated with anti-epileptic drugs is obscure.
5. 4. Methodological considerations
In Studies I-III, data were derived from population-based registers. The Drug Reimbursement
Register covers claims data on 97%-98% of all reimbursed drugs (Finnish Statistics on Medicines
1999, 2003). Timing of exposure could be assessed by a period corresponding to each trimester, as
the drugs to be reimbursed are delivered from pharmacies for a maximum period of three months at
a time. Furthermore, pregnancy is confirmed by ultrasound before applying for maternal grants,
adding to the reliability of the recorded length of gestation. A methodological problem in several
other register-based studies is the lack of information on gestation length, which has been assessed
indirectly (Andrade et al. 2004; Egen-Lappe and Hasford 2004; Schirm et al. 2004); this may
interfere with the reliability of the estimation of drug use. In Studies I and II, the control group
served not only as a point of comparison with the pregnant women but also reflected general trends
in drug prescription and reimbursement policies.
Validation studies have revealed that data coverage of the Medical Birth Register and the National
Register of Induced Abortions is close to 100%, and data quality of most variables has been reported
to be good in both registers, showing 95% or better agreement with medical records (Teperi 1993;
Gissler et al. 1995, 1996, 2004) (Table 7). In addition, the Medical Birth Register includes maternal
background data, such as parity and tobacco smoking, which could be used in the analysis of Study
III. However, no data on alcohol or street drug use, or on non-prescription drug use are available in
the register and therefore could not be included. Contrary to register-based studies, studies based on
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interviews allow collection of data on OTC drugs and vitamin use. However, problems with such
studies include recall bias if the interview is done as late as after delivery (Czeizel et al. 2003). In
addition, unfavourable pregnancy outcome may increase this bias (Rockenbauer et al. 2001).
All neonates are examined by a paediatrician before discharge from the hospital, and diagnoses of
possible illness or malformations are recorded in the Medical Birth Register. By including data from
the Register of Induced Abortions, all pregnancy terminations due to fetal malformation could be
included in the analysis. The Malformation Register classifies a congenital anomaly as a major
congenital structural anomaly, chromosomal defect or congenital hypothyroidism (STAKES 2005).
Major anomalies in this register do not include hereditary diseases, tissue or organ dysfunction,
developmental disabilities or congenital infections (STAKES 2005), and the registry uses the
European Surveillance of Congenital Anomalies (EUROCAT 2005) definitions and guidelines to
exclude minor anomalies. No validation studies are available on the accuracy of the Malformation
Register, but its coverage is considered good (STAKES 2005). Data derived from the Malformation
Register provided additional cases of malformations, which were detected after hospital discharge, and
were therefore not reported in the Birth Register. It is therefore likely that virtually all malformations
were recorded in our study. Only singleton pregnancies were included because twinning is known to
increase the risk of several perinatal complications.
Even cohort studies with large numbers of subjects may be insufficient to detect rare outcomes such
as specific organ system malformations (Olsen et al. 2002). Assuming a 3% baseline risk of major
congenital malformations, a sample of 750 or more is needed to detect a twofold increase in risk. In
these situations, a case-control approach may be more informative. In Study III, however, a cohort
study design was chosen to allow the detection of different endpoints of possible developmental
toxicity.
 Study IV was based on clinical examination and reviewing of medical records and photographs of
the families. Case reports and case series can be valuable for hypothesis generation and for testing in
cohort or case-control studies. Furthermore, when considering rare events, such as specific
congenital malformations or pattern of malformations, case series may − by providing clinical
description of patients − yield additional information regarding already proven causality. Several
factors, including timing of exposure, must be critically evaluated when causality between exposure
and outcome is suspected. Because of the lack of a control group, the rate of adverse outcome could
not be determined.
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6. GENERAL DISCUSSION
According to the study results, prescription drug use during pregnancy is relatively common.
However, a declining trend was observed in the use of several drug groups as pregnancy advanced.
As expected, in chronic illnesses requiring treatment, drug therapy continued during pregnancy. In
general, the findings seem to suggest rational drug prescription and drug use policy. However, the
relatively frequent use of drugs during the first trimester highlights the importance of avoiding
unnecessary treatments in women of child-bearing potential already before pregnancy.
Register-based studies provide a large, population-based data for analysis, and several sources of
bias encountered in studies based on interviews can be avoided. On the other hand, data on actual
drug intake, including timing and duration of exposure, are not available. Furthermore, due to
possible non-compliance in drug intake, drug use may be overestimated. Studies assessing
compliance in drug intake in pregnant women have shown that drugs used for chronic illnesses are
nearly always taken, whereas compliance may be lower with short-term drug therapies (de Jong van
der Berg et al. 1999; Olesen et al. 2001; Olsen et al. 2002). While it is therefore not possible to
estimate drug use directly, the large numbers of subjects in register-based studies partly overcome
this bias.
Our results confirm that drug safety classifications provide a very rough estimate of risk for adverse
fetal effects. These classifications can be used in pharmacoepidemiological studies, but relying on
classification in individual risk assessment may lead to oversimplification. Several drugs classified
as harmful are only harmful during a critical period of fetal development (Kalter 2003).
Accordingly, risk assessment should always be made individually in counselling situations,
including careful evaluation of timing of exposure. In studies assessing drug use during pregnancy,
the varying results reported for different countries may be partly due to different reimbursement
regulations. However, cultural differences and differences in health policy issues are probably the
important determining factors.
 No statistically significant increased risk of major malformations, preterm birth or low birth weight
was found in mothers using SSRIs. The study had 85% power to detect a twofold increase in major
malformations. In the fluoxetine group, an increased risk of major malformations, mainly VSDs,
was observed, but after adjusting for confounders the correlation was no longer statistically
significant, suggesting that factors other than drug exposure may play a major role in adverse
outcome. The preliminary findings of an association between paroxetine use and cardiovascular
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malformations (Diav-Citrin et al. 2005; GlaxoSmithKline Clinical Trial Register 2005) raise some
concern. On the other hand, while VSDs are recorded as major malformations, they often close
spontaneously. The prevalence of non-complex malformations, such as VSDs, vary due to
differences in methods and activity of ascertainment, whereas the prevalence of more serious
malformations do not tend to vary (Bosi et al. 2003). In several reports, paroxetine exposure in the
third trimester has been correlated with severe neonatal problems (Costei et al. 2002; Laine et al.
2004; Sanz et al. 2005). Because of the frequent occurrence of neonatal problems in this group,
these children may be examined more thoroughly after birth than those not exposed, allowing less
severe malformations − easily going undetected in the absence of symptoms – to be ascertained
more frequently.
A statistically significant increased risk of treatment in neonatal special or intensive care units was
found in children exposed to SSRIs in late pregnancy. Accordingly, pregnant women using SSRIs in
the third trimester should deliver in hospitals where paediatric care is available immediately after
birth.
The registers used in the present study did not include information on later neurodevelopment of the
children. Two prospective studies with partially overlapping cases did not find differences in school-
age children exposed to SSRIs in neurobehavioural performance or intelligence (Nulman et al. 1997,
2002). A study comparing children of depressed mothers with and without medication suggested
subtle adverse effects in psychomotor development in children exposed to SSRIs in utero compared
with non-exposed controls (Casper et al. 2003). The sample size was, however, small, and alcohol
consumption in mothers using medication was more frequent than in the control group (Casper et al.
2003). In another small study, neonatal neurobehavioural differences were associated with SSRI
exposure compared with non-exposed controls (Zeskind and Stephens 2004). Furthermore,
diminished pain response has been observed in infants after exposure in utero to SSRIs (Oberlander
et al. 2005). The possible long-term effects on neurodevelopment warrant further studies (Gentile
2005; Morrison et al. 2005; Moses-Kolko 2005; Ruchkin and Martin 2005). Animal studies suggest
that early exposure can disrupt the normal maturation of the serotonin system and have long-lasting
effects on behaviour (Maciag et al. 2005). On the other hand, duration of maternal depression
correlates negatively with cognitive and language development in children (Nulman et al. 2002),
emphasizing the need for careful balancing between the risks and benefits of treatment.
Furthermore, abrupt discontinuation of treatment may lead to increased risk to the mother and
should be avoided (Einarson et al. 2001).
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The characteristic facial features of valproate embryopathy observed in all siblings and the typical
malformations observed in most children of the three families strongly suggest hereditary
susceptibility to valproate-induced adverse outcome. The developmental delay established in all of
our valproate embryopathy patients further implicates valproate neurotoxicity, as no other factors
were found to predispose to this adverse outcome. Valproate is considered a first-line anti-epileptic
drug in generalized-onset and unclassifiable seizure disorders (McCorry et al. 2004) but is also used
in combinations and other indications, including bipolar disorders and migraine prophylaxis
(Viguera et al. 2002; Johannessen and Johannessen 2003; Spina and Perugi 2004). In epilepsy
treatment, seizure control is essential. When possible, other alternatives for valproate should be
considered before pregnancy, especially if previous children in the family have been affected. When
valproate is used for indications other than epilepsy, a change to a safer drug treatment should be
made when planning pregnancy.
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7. SUMMARY AND CONCLUSIONS
An overall tendency towards diminished drug exposure during pregnancy was seen, but medication
for chronic illnesses requiring treatment continued throughout pregnancy. The results are thus in line
with rational drug use during pregnancy. However, although prescriptions for potentially or clearly
harmful drugs decreased during the first and second trimesters, many women were exposed to these
drugs during the period of organogenesis. When prescribing drugs to women of child-bearing
potential, the safety of the drug in view of eventual pregnancy should be considered. Risk
assessment must always be made on an individual basis. Drug safety classifications give a very
crude estimate of risk and should be used only as general guidelines when planning treatment.
No statistically significant increase in the risk of major malformations was found after exposure to
the SSRI-class of drugs in early pregnancy. Women with fluoxetine exposure in the first trimester
were more likely to have malformed offspring; after adjusting for confounders, the association
between drug exposure and malformations remained almost statistically significant (OR 1.7, 95% CI
0.9-3.3). Our findings support the previous reports and studies of increased risk of neonatal
problems after exposure to SSRIs in the third trimester. We found a statistically and clinically
significant increased risk for treatment in a neonatal special or intensive care unit after third-
trimester exposure (adjusted OR 1.6, 95% CI 1.1-2.2). Our results do not, however, confirm
previous findings of an SSRI-related risk of preterm birth or low birth weight. Nevertheless, SSRIs
should be used in pregnancy only when clearly indicated. The SSRI drug dose should be the lowest
that allows adequate treatment of the illness, and when possible, treatment should be discontinued
two to three weeks before the expected delivery date. Due to the relatively common occurrence of
neonatal problems, women using SSRIs should deliver in units where paediatrician consultation is
available without significant delay.
While the mechanism of valproate teratogenicity remains unknown, genetic factors are probably
important in determining the teratogenic potential of valproate. In addition to the established risk of
major malformations, the risk of neurodevelopmental delay may be increased. Alternative anti-
epileptic drugs should be considered before pregnancy, especially if previous offspring in the family
have been affected. When valproate is used for indications other than epilepsy, a change to a safer
drug treatment should be made already in the pregnancy-planning stages.
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